Coordinated interactions between endothelial cells and macrophages in the islet microenvironment promote β cell regeneration

Diane C. Saunders[1,2]*, Kristie I. Aamodt[1]*, Tiffany M. Richardson[1], Alec Hopkirk[2], Zoya Khan[2], Radhika Aramandla[2], Greg Poffenberger[2], Regina Jenkins[2], David K. Flaherty[3], Nripesh Prasad[4], Sean E. Levy[4], Alvin C. Powers[1,2,5], and Marcela Brissova[2]

*D.C.S. and *K.I.A. contributed equally to this work.

[1]Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN

[2]Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN

[3]Flow Cytometry Shared Resource, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[4]Hudson Alpha Institute of Biotechnology, Huntsville, AL

[5]VA Tennessee Valley Healthcare, Nashville, TN

Address correspondence to:

Marcela Brissova
Vanderbilt University Medical Center
7465 MRB IV
2215 Garland Avenue
Nashville, TN 37232-0475
marcela.brissova@vumc.org
(615) 936-7678

Alvin C. Powers
Vanderbilt University Medical Center
7465 MRB IV
2215 Garland Avenue
Nashville, TN 37232-0475
al.powers@vumc.org
(615) 936-7678

ABSTRACT

Endogenous β cell regeneration could alleviate diabetes, but proliferative stimuli within the islet microenvironment are incompletely understood. We previously found that β cell recovery following hypervascularization-induced β cell loss involves interactions with endothelial cells (ECs) and macrophages (MΦs). Here we show that proliferative ECs modulate MΦ infiltration and phenotype during β cell loss, and recruited MΦs are essential for β cell recovery. Furthermore, VEGFR2 inactivation in quiescent ECs accelerates islet vascular regression during β cell recovery and leads to increased β cell proliferation without changes in MΦ phenotype or number. Transcriptome analysis of β cells, ECs, and MΦs reveals that β cell proliferation coincides with elevated expression of extracellular matrix remodeling molecules and growth factors likely driving activation of proliferative signaling pathways in β cells. Collectively, these findings suggest a new β cell regeneration paradigm whereby coordinated interactions between intra-islet MΦs, ECs, and extracellular matrix mediate β cell self-renewal.

INTRODUCTION

While investigating how vascular endothelial growth factor-A (VEGF-A) regulates islet vascularization, our group previously characterized a mouse model in which signals from the local microenvironment stimulate β cell self-renewal[1]. In this model, transiently increasing VEGF-A production in β cells (βVEGF-A) induces endothelial cell (EC) expansion and hypervascularization that causes β cell loss; remarkably, islet morphology, capillary network, β cell mass, and function normalize 6 weeks after withdrawal (WD) of the VEGF-A stimulus. This regenerative response is a result of a transient but robust burst in β cell proliferation, which is dependent on VEGF-A-mediated recruitment of macrophages (MΦs). These recruited cells express markers of both pro-inflammatory (M1) and restorative (M2) activation, suggesting a unique regenerative phenotype[1–5]. Further investigation into the role of various microenvironmental components on β cell proliferation in this model is needed given that this regenerative microenvironment promotes proliferation of human in addition to mouse β cells[1].

MΦs are often perceived as damaging to islets due to their role in β cell loss during diabetes[6–8], but it is becoming increasingly appreciated that tissue-resident MΦs play important roles in immune surveillance and tissue homeostasis and function in the islet. Mice with compromised MΦ populations during pancreatic development exhibit reduced β cell proliferation, β cell mass,

29 and impaired islet morphogenesis[9,10]. Furthermore, recent studies have supported the notion
30 that MΦs contribute to β cell regeneration after several types of injury, including surgically
31 induced pancreatitis[11] and diphtheria toxin (DT)-mediated apoptosis[12]. This recent work
32 highlights the importance of understanding how MΦs contribute to β cell proliferation and further
33 defining MΦ phenotype and function in the βVEGF-A model.

34 In addition to MΦs, ECs are known to participate in tissue repair via activation of the VEGF-A–
35 VEGFR2 pathway, which mediates angiocrine factor production and promotes local cell renewal
36 and regeneration[13–16]. There is a precedent for ECs facilitating tissue repair by influencing MΦ
37 activation toward a restorative, M2-like phenotype[4]. Because vasculature is essential for normal
38 islet function, understanding signals that govern EC homeostasis and the effects of ECs on
39 neighboring cell populations is crucial for maintaining and restoring islet health. Signaling
40 between ECs and the pancreatic epithelium is critical for establishing islet vasculature and β cell
41 mass during development, and in mature islets ongoing signaling between endocrine and ECs
42 is required to maintain the capillary network through which endocrine cells receive adequate
43 nutrition and oxygen and can rapidly sense and secrete hormones[17–19]. The vascular basement
44 membrane is also the primary component of the intra-islet extracellular matrix (ECM) and acts
45 as a reservoir for growth factors and other signaling molecules important for β cell
46 differentiation, function, and proliferation[20–23]. In the βVEGF-A model, ECs may affect the
47 regenerative process indirectly by promoting MΦ recruitment and activation, altering ECM
48 composition and signaling, and/or by directly influencing β cell proliferation.

49 Here we deconstructed the complex *in vivo* islet microenvironment in the βVEGF-A model and
50 show that β cell self-renewal is mediated by coordinated interactions between recruited MΦs,
51 intra-islet ECs, and the ECM (**Figures 1, S1**). To isolate the roles of MΦs and ECs in this model
52 we removed MΦs from the islet microenvironment (**Figures 1, S1**; experimental scheme **A**) and
53 inactivated VEGFR2 signaling in ECs to discern the effects of proliferative or quiescent ECs on
54 β cell proliferation (**Figures 1, S1**; experimental schemes **B** and **C**). Since the βVEGF-A islet
55 microenvironment is a complex *in vivo* system involving dynamic changes in islet cell
56 composition, we also identified regenerative signals by performing transcriptome analysis
57 (**Figures 1, S1**; experimental scheme **D**) of purified islet cell populations including β cells, ECs,
58 and MΦs over the course of β cell loss and recovery. Based on previous work[1,16] we predicted
59 that either MΦ depletion (clodronate) or loss of VEGFR2 signaling in ECs would perturb MΦ
60 recruitment and polarization and impair β cell regeneration. Indeed, we found that MΦ depletion
61 suppressed the transient burst in β cell proliferation leading to reduced recovery of β cell mass.

62 In addition, VEGFR2-mediated signaling in intra-islet ECs was necessary for maximal MΦ
63 recruitment and M2-like phenotype activation. Surprisingly, VEGFR2 ablation in quiescent ECs
64 during the period of β cell recovery accelerated islet vascular regression leading to increased β
65 cell proliferation while MΦ phenotype and number was unchanged. Transcriptome analysis
66 during β cell death and recovery revealed intricate changes in expression of growth factors,
67 integrins, and matrix remodeling enzymes in all three cell types, suggesting that ECM
68 remodeling and activation of ECM-associated molecules within the islet microenvironment play
69 critical roles in β cell self-renewal. Taken together, our results indicate that both MΦs and intra-
70 islet ECs provide crucial microenvironmental cues to cooperatively promote β cell regeneration.



Figure 1. The RIP-rtTA; Tet-O-VEGF-A (βVEGF-A) model of β cell regeneration permits specific modulation of the islet microenvironment. Induction of VEGF-A overexpression in β cells with doxycycline (Dox) causes rapid endothelial cell (EC) expansion, β cell death, and recruitment of circulating monocytes increasing the number of intra-islet macrophages (MΦs). Once the Dox stimulus is removed, VEGF-A levels normalize and β cells undergo self-renewal[1]. **(A)** To establish the role of MΦs in β cell proliferation, monocytes and MΦs were depleted with clodronate liposomes. **(B)** To determine whether proliferative intra-islet ECs were required for β cell loss, MΦ recruitment, and MΦ phenotype activation, an additional genetic construct was introduced to knock down key signaling receptor VEGFR2 in ECs prior to VEGF-A induction. **(C)** To determine if VEGFR2 signaling in quiescent ECs contributes to β cell proliferation, VEGFR2 was inactivated in ECs during β cell recovery. **(D)** To identify cell-specific transcriptome changes during β cell loss and recovery, populations of ECs, MΦs, and β cells were isolated prior to and during VEGF-A induction, and after VEGF normalization. For additional details, including mouse models utilized, see **Figure S1**.

RESULTS

71 We previously developed the βVEGF-A model, which allows for Dox-induced, β cell-specific
72 overexpression of VEGF-A causing rapid intra-islet EC expansion, widespread β cell loss, and
73 MΦ recruitment to islets from a pool of circulating monocytes[1]. When Dox is removed and

74 VEGF-A levels normalize, ECs return to baseline levels, but MΦs persist in the islet
75 microenvironment, and β cells undergo a transient but robust proliferation that leads to β cell
76 mass restoration (**Figure 1**).

77 ***Chemical depletion of macrophages in βVEGF-A islets inhibits β cell proliferation***
78 To dissect pathways and signaling molecules in the islet microenvironment required for β cell
79 recovery, we first employed clodronate-mediated MΦ depletion which impacts both infiltrating
80 and islet resident MΦs. Clodronate is an ATP/ADP translocase inhibitor, and when packaged
81 into liposomes it is selectively taken up by MΦs due to their phagocytic properties and causes
82 apoptosis. We treated βVEGF-A mice with either control or clodronate liposomes starting one
83 day before VEGF-A induction and continuing for one week after VEGF-A normalization (**Figure**
84 **2A**). Compared to control, clodronate treatment reduced circulating $CD11b^{+}$ $Ly6G^{-}$ monocytes
85 by 50% within 24 hours (**Figure 2B,** *No Dox*) and reduced the MΦ population in islets by 94%
86 one week after VEGF-A induction (**Figure 2C** and **2D,** *1wk Dox*). MΦ depletion was maintained
87 during VEGF-A normalization, with 86% fewer MΦ in islets from clodronate-treated βVEGF-A
88 mice one week after Dox withdrawal (**Figure 2C** and **2D,** *1wk WD*). VEGF-A induction in
89 clodronate-treated mice led to increased EC area (**Figures 2C** and **2E**) and β cell loss (**Figures**
90 **2B** and **2F**) comparable to βVEGF-A mice treated with control liposomes, thus demonstrating
91 that clodronate treatment and MΦ depletion did not influence intra-islet EC expansion and
92 hypervascularization-induced β cell loss. In contrast, MΦ depletion significantly impaired β cell
93 proliferation during the recovery period (8.5 vs. 2.1%, $p<0.001$; **Figure 2G**) and resulted in
94 reduced β cell area compared to controls after 6 weeks of VEGF-A normalization (**Figure 2F**),
95 demonstrating that MΦs are required for the regenerative response in βVEGF-A islets.
96 Interestingly, β cell area is slightly but significantly increased one week after Dox withdrawal
97 (**Figure 2F**, *1wk WD*) in clodronate-treated βVEGF-A mice before ultimately the impaired β
98 proliferation leads to reduced β cell area 6 weeks after VEGF-A normalization. This finding
99 suggests that MΦs play an important role in islet remodeling and composition in βVEGF-A mice
100 separate from their effect on β cell proliferation, most likely through their function as phagocytes.

101 ***Proliferative ECs are required for MΦ polarization and maximal MΦ recruitment***
102 To investigate the contribution of ECs to β cell loss and recovery in the βVEGF-A model, we first
103 created a mouse line in which VEGFR2, which is enriched in ECs of islet capillaries and the
104 main transducer of VEGF-A signal in islets, is inactivated by tamoxifen (Tm)-inducible Cre-
105 mediated excision in ECs. We initially tested the EC-SCL-$CreER^{T}$ transgene[24], which contains a



Figure 2. Macrophages are required for β cell proliferation in βVEGF-A mice. (A) To deplete macrophages (MΦs) during VEGF-A induction and normalization, βVEGF-A mice were treated with clodronate or control liposomes (150-200 µl i.v.) every other day, beginning one day before Dox treatment and continuing 1 week after Dox withdrawal (1wk WD). **(B)** Representative flow cytometry plots showing circulating monocytes ($CD11b^+$ $Ly6G^-$) of control and clodronate-treated βVEGF-A mice 24 hours after single injection (No Dox). Approximately 10,000 white blood cells (WBCs) were analyzed and quantified (mean±SEM) per each animal. **(C)** Islet architecture displayed by labeling for β cells (Insulin; blue), endothelial cells (Caveolin-1; green), and MΦs (Iba1; red) during VEGF-A induction (1wk Dox) and normalization (1wk WD). Scale bar, 50 µm. **(D)** Quantification (mean±SEM) of islet MΦ area by immunohistochemistry (5.1±0.7 x 10^5 μm^2 total islet area analyzed per animal). **(E–F)** Quantification (mean±SEM) of endothelial cell (EC) area **(E)** and β cell area **(F)** in βVEGF-A mice treated with control or clodronate liposomes during VEGF-A induction and normalization. **(G)** Rate of β cell proliferation (mean±SEM; 1,138±87 β cells counted per animal) during VEGF-A normalization (1wk WD and 2wk WD) in control βVEGF-A mice was significantly reduced in clodronate-treated mice. In panels **(B–G)** each closed circle represents one animal; asterisks indicate unpaired t-tests of control vs. clodronate groups; *, $p<0.05$; **, $p<0.01$; ****, $p<0.0001$. Dashed lines in **D–G** depict average values in βVEGF-A mice at baseline (No Dox).

106 5' endothelial enhancer for the stem cell leukemia (SCL) transcription factor, and although Cre
107 activity was confirmed in islet ECs using the *Gt(ROSA)26Sor*^{tm1Sor} reporter strain[25], VEGFR2
108 expression was unchanged in EC-SCL-CreER^{T}; VEGFR2$^{fl/fl}$ mice (data not shown). Fortunately,
109 were able to obtain the Cad5-CreER^{T2} line[26] and achieved efficient EC-specific VEGFR2
110 knockdown in Cad5-CreER^{T2}; VEGFR2$^{fl/fl}$ (VEGFR2$^{i\Delta EC}$) mice. Pancreata harvested after 3
111 doses of Tm were evaluated to confirm VEGFR2 ablation (**Figures S2A** and **S2B**) without
112 significant changes in islet capillary density or size (**Figures S2C** and **S2D**) or basal β cell
113 proliferation (**Figure S2E**), indicating that acute loss of VEGFR2 signaling in ECs is not
114 detrimental to adult islet vascular homeostasis or β cell proliferation. A similar observation was
115 made previously when VEGF-A was acutely inactivated in adult β cells[18]. Next, we crossed
116 VEGFR2$^{i\Delta EC}$ mice with the existing βVEGF-A line to effectively perturb VEGF-A–VEGFR2
117 signaling in ECs at various time points during β cell loss and recovery. To control for any
118 possible effects of Tm administration on compensatory β cell proliferation[27], we treated all mice
119 with Tm and designated Cre-negative (βVEGF-A; VEGFR2$^{fl/fl}$) mice as controls to represent
120 intact VEGFR2 signaling by ECs.

121 To determine the effect of proliferative ECs on MΦ recruitment and polarization, Tm was
122 administered to knock down VEGFR2 (R2) in ECs prior to VEGF-A induction in β cells (**Figures**
123 **3A** and **S3A**). VEGF-A was induced in both control βVEGF-A; R2$^{fl/fl}$ and βVEGF-A; R2$^{i\Delta EC}$
124 genotypes, with efficient knockdown of VEGFR2 in the latter (**Figure S3B**). As expected, VEGF-
125 A induction caused a 7% EC expansion and associated 16% β cell loss per islet area in βVEGF-
126 A; R2$^{fl/fl}$ controls, whereas EC and β cell area did not change in βVEGF-A; R2$^{i\Delta EC}$ mice (**Figures**
127 **3B-D**). These results indicate that activation of VEGFR2 signaling in ECs by acute elevation of
128 VEGF-A in the islet microenvironment is essential for islet hypervascularization and leads to β
129 cell loss.

130 Inactivation of VEGFR2 signaling in ECs significantly reduced, but did not completely prevent
131 MΦ recruitment to βVEGF-A; R2$^{i\Delta EC}$ islets compared to βVEGF-A; R2$^{fl/fl}$ controls (5.0 vs. 6.3%
132 per total islet area, respectively; $p<0.05$) (**Figures 3E** and **3F**). This suggests that MΦ infiltration
133 can occur in response to VEGF-A alone, which is consistent with the fact that VEGF-A can
134 mediate monocyte recruitment through VEGFR1 activity[28,29]. Still, the proliferative EC
135 environment (intact VEGF-A–VEGFR2 signaling and β cell loss) leads to maximal MΦ
136 recruitment. Interestingly, a subset of infiltrating MΦs in control islets expressed the M2-like
137 marker CD206 (Mrc1), which is normally made only by exocrine MΦs[30,31], while infiltrating MΦs
138 in βVEGF-A; R2$^{i\Delta EC}$ islets remained CD206^{-} (**Figures 3E** and **3G**). This observation suggests



Figure 3. Inactivation of VEGFR2 signaling in endothelial cells prevents β cell loss and M2-like macrophage polarization by acute elevation of VEGF-A in the islet microenvironment. (A) To inactivate VEGFR2 in endothelial cells (ECs), control (βVEGF-A; VEGFR2$^{fl/fl}$) and VEGFR2$^{i\Delta EC}$ (βVEGF-A; VEGFR2$^{i\Delta EC}$) mice were treated with Tamoxifen (Tm; 4mg s.c.) prior to VEGF-A induction. **(B)** Islet architecture displayed by labeling for macrophages (Iba1$^+$), ECs (CD31$^+$), and β cells (Ins$^+$) at baseline (No Dox) and after 3d Dox. **(C–D)** Quantification (mean+SEM) of islet β cell and EC composition (10±1 x 10^5 μm^2 total islet area analyzed per animal). **(E)** Some intra-islet macrophages (MΦs) in control mice showed an "M2-like" phenotype (CD206$^+$) after VEGF-A induction, indicated by arrowheads. Insets show representative intra-islet MΦs in each group and time point. **(F–G)** Quantification (mean±SEM) of MΦ infiltration and M2-like intra-islet MΦs (percent CD206$^+$ Iba1$^+$ of Iba1$^+$), 3±2 x 10^5 μm^2 total islet area analyzed per animal. Each closed circle in bar graphs represents one animal. Asterisks indicate unpaired t-tests between genotypes; *, $p<0.05$; ***, $p<0.001$. Scale bars in **(B)** and **(E)**, 50 μm; inset, 10 μm.

139 that VEGFR2 signaling in proliferative ECs and/or β cell loss promotes MΦ polarization to an
140 M2-like phenotype.

141 ***VEGFR2 inactivation in quiescent ECs accelerates EC regression, enhancing β cell***
142 ***recovery***

143 To investigate the role of VEGFR2 signaling in quiescent ECs during β cell recovery, VEGF-A-
144 mediated EC proliferation and β cell loss was first induced with 3-day Dox treatment in βVEGF-
145 A; R2$^{i\Delta EC}$ mice and controls, followed by 7 days of Dox withdrawal to allow VEGF-A to normalize
146 and ECs to return back to quiescence (**Figures 4A, S4A**). Islet phenotype and β cell
147 proliferation was assessed after 7 days of VEGF-A normalization (7d WD) and subsequently 2
148 days post-Tm treatment to inactivate VEGFR2 (9d WD). VEGF-A-induced EC expansion, β cell
149 loss, and MΦ infiltration occurred in both genotypes, with no difference between the two groups
150 at 7d WD prior to VEGFR2 inactivation (**Figures 4B-E**). As expected, VEGF-A expression
151 continued to decline during Dox withdrawal and VEGFR2 was efficiently inactivated in βVEGF-
152 A; R2$^{i\Delta EC}$ mice within 48 hours of a single 4-mg Tm injection (**Figure S4B**). Surprisingly, unlike
153 under normal homeostatic conditions (**Figure S2**), VEGFR2 inactivation in βVEGF-A; R2$^{i\Delta EC}$
154 mice significantly accelerated islet EC regression compared to controls (**Figure 4D**) without
155 changes in MΦ phenotype (**Figure S4C**) and number (**Figure 4C**), suggesting that neither MΦ
156 retention nor polarization at this stage of β cell recovery are dependent on VEGFR2 signaling in
157 quiescent ECs.

158 Since VEGFR2 inactivation in quiescent ECs of βVEGF-A; R2$^{i\Delta EC}$ mice leads to a relatively rapid
159 EC decline after Tm treatment (9d WD), we next evaluated the islet vascular regression by
160 visualization of collagen IV, a major component of the islet ECM[32,33] generated by intra-islet
161 ECs. This study revealed that regressing islet capillaries leave behind vascular "casts" of ECM
162 that are no longer associated with intact ECs (**Figure 4F,** *9d WD*). Even more surprising was
163 our finding that this accelerated decline in islet ECs enhances β cell proliferation at 9d WD
164 (**Figure 4G**). We hypothesize that in contrast to β cell homeostasis, the regression of quiescent
165 ECs during the β cell recovery phase stimulates release of growth factors from degraded ECM,
166 thereby promoting β cell proliferation (**Figure 4H**).

167 ***Identifying interactions between β cells, ECs, and MΦs in the βVEGF-A islet***
168 ***microenvironment***

169 Our prior studies in the βVEGF-A model localized the stimulus for β cell proliferation to the islet
170 microenvironment, ruling out any contribution from circulating factors that might reach the



Figure 4. Phenotypic and structural changes to the islet microenvironment in response to VEGFR2 inactivation in quiescent endothelial cells during β cell recovery. (A) To inactivate VEGFR2 in endothelial cells (ECs) during β cell recovery, control (βVEGF-A; VEGFR2$^{fl/fl}$) and VEGFR2$^{i\Delta EC}$ (βVEGF-A; VEGFR2$^{i\Delta EC}$) mice received Tamoxifen (Tm; 4mg s.c.) after 7 days (d) of Dox withdrawal (WD). **(B)** Islet architecture visualized by labeling for macrophages (Iba1$^+$) ECs (CD31$^+$, green), β cells (Insulin$^+$, blue) at 7d WD (pre-Tm) and 9d WD (2d post-Tm). Scale bar, 50 μm. **(C–E)** Area quantification (mean±SEM) of islet ECs (**C**), MΦs (**D**), and β cells (**E**) by immunohistochemistry; 14±1 x 10^5 μm^2 total islet area analyzed per animal. Each circle represents one animal; asterisks indicate results of unpaired t-tests between genotypes; ***, p<0.001. (**F**) Visualization of islet extracellular matrix by immunofluorescence (ECM; Col-IV$^+$, red), ECs (CD31$^+$, green), β cells (Insulin$^+$, blue) at 7d WD (pre-Tm) and 9d WD (2d post-Tm). Scale bar, 50 μm; inset, 10 μm. Arrowhead in **(F)** points to ECM casts where ECs have regressed. **(G)** β proliferation rates (1,947±145 β cells per animal) plotted as a function of β cell loss (% β cells of total islet area) reveal a significant increase after VEGFR2 inactivation in quiescent ECs at 9d WD. Parentheses beside lines provide x- and y-intercepts derived from linear regression. At 9d WD, intercepts are significantly different; **, p<0.01. **(H)** Schematic of proposed mechanism for increased β cell area observed in VEGFR2$^{i\Delta EC}$ mice.

171 pancreas[1]. With key roles established for both MΦs and ECs in this system, we next sought to
172 identify potential mechanisms and signaling pathways coordinating cell-cell and cell-matrix
173 interactions. To do this we isolated βVEGF-A islets at baseline (No Dox) and during the course
174 of VEGF-A induction (1wk Dox) and normalization (1wk WD) and purified islet populations of β
175 cells, ECs, and MΦs at each of these time points for transcriptome analysis (**Figures 5A, S5A**
176 and **S5B**).

177 All of the nine sample types analyzed (3 cell types per each of 3 time points) demonstrate
178 distinct transcriptional profiles, reflecting a high degree of uniqueness among three cell types
179 and significant temporal changes in gene expression within each cell type (**Figures S5C-E**). By
180 hierarchical clustering, the highest correlations were observed within one cell type across
181 different time points; for example, β cells at No Dox are more similar to β cells at 1wk Dox and
182 1wk WD than they are to MΦs or ECs at any time point. Of the β cell samples, regenerative β
183 cells (1wk WD) are more similar to stressed β cells (1wk Dox) than quiescent β cells (No Dox);
184 in contrast, regenerative MΦs (1wk WD) are more similar to resident MΦs (No Dox) than to
185 those recruited upon VEGF-A induction (1wk Dox), and quiescent ECs following VEGF-A
186 normalization (1wk WD) are more similar to quiescent ECs at baseline (No Dox) than to
187 proliferative ECs (1wk Dox) (**Figure S5D**).

188 With the induction of VEGF-A (1wk Dox), all cell populations increase expression of growth
189 factors, matrix remodeling enzymes involved in tissue repair and matrix degradation (MMPs,
190 ADAMs, ADAMTSs), as well as cell adhesion molecules involved in cell-matrix and cell-cell
191 interactions (ICAM1, VCAM1, selectins), many of which remain elevated during β cell
192 regeneration (1wk WD) (**Figure S6A**). Pathway analysis shows a high degree of cellular motility
193 (**Figure S6B**), and extracellular organization and cell adhesion processes are significantly
194 enriched in all cell types during β cell recovery (**Figure S7**).

195 Infiltrating MΦs show elevated expression of both pro-inflammatory and pro-regenerative
196 markers during periods of initial monocyte recruitment (1wk Dox) and β cell regeneration (1wk
197 WD). Pro-inflammatory genes like *Il12b* and *Il1a* are upregulated at 1wk Dox, while M2 markers
198 such as *Ptgs1* and *Retnla* are upregulated and/or remained elevated at 1wk WD (**Figure S6A**).
199 Upregulation of chemokines and cytokines by MΦs and corresponding increase in expression of
200 receptors (e.g., *Cxcr4*, *Il12rb2*) by β cells suggests crosstalk between the two cell types and
201 potential phenotypic effects on β cells in addition to MΦs. Similarly, increased growth factor
202 expression in ECs and MΦs appears in concert with increased expression of growth factor
203 receptors in β cells (**Figure S6A**).



Figure 5. Genes and pathways upregulated in β cells during recovery reflect activation of intracellular signaling to promote proliferation. (A) Experimental schematic showing sorting of islet-derived β cells, endothelial cells (ECs), and macrophages (MΦs) from βVEGF-A mice at baseline (No Dox), during VEGF-A induction/β cell loss (1wk Dox), and during VEGF-A normalization/β cell recovery (1wk WD). See also **Figure S5B–E**. **(B)** Normalized expression of selected genes known to function in β cell proliferation[34–37] at No Dox (n=4 replicates), 1wk Dox (n=5), and 1wk WD (n=3). Numbers listed in 1wk Dox and 1wk WD columns represent fold-change ≥2 or <-2 ($p<0.05$) as compared to No Dox. **(C)** Selected differentially regulated pathways during β cell recovery (1wk WD vs. No Dox), as determined by Ingenuity Pathway Analysis (IPA). Total bar width represents z-score; colored fractions indicate percentage of pathway genes that are up (blue), down (orange), and unchanged (grey). Number of genes per category is also listed within or adjacent to bars. A full list of significantly regulated pathways (z-score ≥2 or ≤-2, $p<0.05$) is provided in **Table S1**. FGF, fibroblast growth factor; HGF, hepatocyte growth factor; ILK, integrin-linked kinase; MAPK, mitogen-activated protein kinase; NFAT, nuclear factor of activated T cells; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K, phosphoinositide 3-kinase; PAK, p21-activated kinase; TREM1, triggering receptor expressed on myeloid cells 1; VEGF, vascular endothelial growth factor.

204 At the peak of regeneration (1wk WD), β cells highly express integrins and other molecules that
205 sense and respond to changes in the extracellular milieu (**Figure 5B**). Activation of integrin-
206 mediated signaling and the integrin-linked kinase pathway were accompanied by increases in
207 PI3K/Akt and MAPK signaling genes (**Figures S7A** and **5C**), many of which are known
208 modulators of β cell proliferation[34–37]. Transcriptional activators *Cdk6* and *Foxm1* are initially
209 upregulated more than 3-fold compared to baseline, followed by downregulation of suppressor
210 *Cdkn2c* (p18) specifically during β cell recovery, consistent with previous studies of both mouse
211 and human β cells[38–40]. *Creb5* and *Ets1* are notably increased as well. Collectively, these data
212 provide evidence for a model where β cell proliferation is largely driven through MΦ–EC–β cell
213 paracrine signaling, ECM remodeling, and cell-matrix interactions (**Figure 6**).



Figure 6. Model of interactions between β cells, macrophages, endothelial cells, and the extracellular matrix in β cell regeneration. Upon VEGF-A induction, intra-islet endothelial cells (ECs) proliferate while increasing expression of cell adhesion molecules and growth factors and altering their expression of integrins and extracellular matrix (ECM) remodeling enzymes. These adhesion molecules help recruit macrophages (MΦs), which upon islet infiltration also upregulate expression of cell adhesion molecules and pro- and anti-inflammatory chemokines and cytokines, influencing further MΦ recruitment in addition to signaling through chemokine and cytokine receptors on β cells. Chemokine and cytokines become increasingly less inflammatory as VEGF-A normalizes, as MΦs produce growth factors and matrix remodeling enzymes that may promote β cell proliferation. Upon VEGF-A induction, β cells exhibit enrichment for several integrin pathways and other proteins involved in ECM remodeling and cell-matrix interactions in addition to regulating expression of chemokines known to support a regenerative (M2 or alternative) MΦ phenotype. Growth factors from all cell types act on an increased number of growth factor receptors being expressed on β cells, activating downstream signals converging on the PI3K/Akt and MAPK pathways. Other signals from cells in the microenvironment, or from the rapidly remodeling ECM, may also play a role in β cell proliferation.

DISCUSSION

214 Adult β cells have a very limited proliferative capacity and signals regulating this process are
215 incompletely understood. The complexity of the islet microenvironment and difficulty modeling
216 this complexity *in vitro* often constrains investigation of β cell proliferation to reductionist
217 approaches, removing components of the *in vivo* environment known to contribute to the
218 establishment and maintenance of β cell mass and thereby limiting the utility of these studies.
219 Here we utilized the βVEGF-A mouse model[1] in which signals from the local islet
220 microenvironment, including β cells, ECs, and MΦs, promote proliferation of human as well as
221 mouse β cells. To dissect how these microenvironmental components influence β cell loss and
222 recovery within the context of this complex and dynamic *in vivo* model, we developed new
223 experimental tools to intricately modulate EC and MΦ populations and their signaling within the
224 islet. These tools, coupled with transcriptional analysis of temporal changes in gene expression
225 patterns of β cells, ECs, and MΦs, allowed us to gain important insight into the cell-cell and
226 ECM-mediated signaling in this model, which work in concert to promote β cell proliferation
227 (**Figure 6**).

228 **Role of macrophages**

229 Our transcriptome analysis suggested that MΦ recruitment to islets is facilitated not only by
230 VEGF-A signaling but also by increased expression of cell adhesion molecules on both MΦs
231 and ECs, as well as increased production of chemokines and cytokines from MΦs already in the
232 islet microenvironment[41]. By specifically depleting MΦs in βVEGF-A mice using clodronate
233 liposomes, we demonstrated that MΦs are required for β cell regeneration in the islet
234 microenvironment. These recruited MΦs have a unique hybrid phenotype: they express markers
235 of both classical pro-inflammatory (M1) activation as well as alternative (M2) activation
236 promoting tissue repair and regeneration. Though MΦ-derived cytokines and chemokines can
237 exacerbate β cell stress[42,43], the comparable β cell loss in MΦ-depleted and control islets
238 suggests that MΦs do not promote β cell apoptosis in this model. Instead, MΦs downregulate
239 key pro-inflammatory cytokines (*e.g.*, *Tnf, Il6*) at 1wk WD, concomitant with β cell proliferation.
240 Their phenotypic profile at this stage is most reminiscent of phenotyping subtypes “M2a” (high
241 expression of scavenger and phagocytic receptors like Retnlb/Fizz2, Ym1, and Mrc1; secretion
242 of profibrotic and trophic factors like fibronectin, IGF, and TGFβ) and “M2c” (associated with
243 removal of apoptotic cells)[44–46]. This phagocytic phenotype is consistent with our finding that
244 MΦs at this time point (1wk WD) likely have an effect on islet remodeling and composition

245 separate from their effect on β cell proliferation. Together, these data suggest a phenotypic shift
246 in MΦs that facilitates β cell recovery and return to homeostasis in the islet, in line with an
247 increasing number of studies observing tissue-restorative effects of MΦs triggered in various β
248 cell injury models[11,12,47]. Further studies will be necessary to clarify the specific signals that
249 regulate the phenotypic shift and define the cues that govern their withdrawal.

250 **Role of endothelial cells**

251 Regulated EC-derived signals are necessary for pancreatic and islet development[17,48–50],
252 optimal adult β cell function[18], and islet revascularization after transplantation[51–54]. In addition,
253 ECs and VEGFR2 signaling have been previously implicated in organ regeneration[13,16]. For
254 example, during liver regeneration, sinusoidal ECs appear to have a biphasic effect in mediating
255 hepatic reconstitution; proliferative angiogenesis of sinusoidal ECs inhibits hepatocyte self-
256 renewal, whereas quiescent sinusoidal ECs stimulate hepatic regeneration[13]. To determine the
257 role of proliferative and quiescent ECs in β cell loss and recovery, we generated a compound
258 βVEGF-A model with inducible VEGFR2 inactivation (βVEGF-A; VEGFR2$^{i\Delta EC}$) that allowed us to
259 modulate VEGF-A–VEGFR2 signaling in ECs.

260 Our studies show that intact VEGFR2 signaling is required for the proliferative angiogenesis of
261 islet endothelium, which ultimately results in β cell loss. Although transcriptome analysis did not
262 reveal specific signals produced by proliferating ECs that would lead to β cell apoptosis during
263 VEGF-A induction, there are significant changes in expression of matrix remodeling enzymes
264 and cell adhesion molecules. Based on the importance of cell-matrix interactions in β cell
265 survival *in vitro*[20,55], we hypothesize that ECM changes associated with rapidly expanding
266 endothelium likely contribute to β cell loss in the βVEGF-A system. In addition, we show that
267 intact VEGFR2 signaling is necessary for accumulation of intra-islet MΦs expressing CD206, a
268 marker of an M2 phenotype. This observation is consistent with MΦ activation by EC-derived
269 cues in the context of acute injury, a phenomenon that has been noted in numerous tissues[56–58].
270 Furthermore, a similar M2 phenotype (high IL-10, CD206) was shown to be required for β cell
271 regeneration after DT-mediated ablation[12], and elsewhere CD206 has been linked to increased
272 expression of *Tgfb1* and *Egf* [59] and promotion of β cell proliferation via a Smad7-cyclin
273 pathway[11].

274 In contrast to lung and liver regeneration[13,16], VEGFR2 inactivation in quiescent ECs (1wk WD)
275 resulted in accelerated β cell recovery, which is associated with rapid islet capillary regression,
276 leaving behind vascular “casts” of ECM components. We postulate that β cell proliferation is

277 promoted by release of growth factors from degraded ECM. Though ECs are no longer
278 expanding at the 1wk WD time point, islets still contain quite extensive capillary networks that
279 might be sustained by the residual extracellular VEGF-A we observed, as well as possibly other
280 growth factors. Interestingly, VEGFR2 inactivation during β cell homeostasis does not impact β
281 cell proliferation and islet capillary morphology. It will be important to assess the role of
282 quiescent ECs and VEGFR2 signaling in other β cell injury models in the future. In addition,
283 these findings highlight that ECs have different roles in different tissues and during various
284 physiologic and pathologic stressors.

285 **Role of extracellular matrix and integrated cellular interactions in β cell proliferation**

286 By deconstructing the contributions of the cellular components of the islet microenvironment of
287 βVEGF-A mice, we were able to uncover a role for ECM remodeling and signaling in β cell
288 proliferation. MΦs, ECs, and β cells all show transcriptional regulation of integrin receptors and
289 ECM remodeling enzymes, some of which have been shown previously to affect β cell
290 proliferation[22,60–62]. In addition to shaping cell-matrix signaling, ECM reorganization can also
291 lead to the release and/or activation of matrix-sequestered growth factors[63–66]. This is
292 particularly relevant given the temporal increase of growth factor receptor expression in β cells
293 during VEGF-A induction and normalization, suggesting heightened β cell responsiveness to
294 signals from the rapidly remodeling ECM as VEGF-A normalizes. Together, these data provide
295 evidence that ECM-bound growth factors released during EC regression promote β cell
296 proliferation.

297 Remodeling of extracellular milieu can also influence MΦ phenotype[67,68], though more work is
298 required to define specific signaling pathways that regulate this process in the pancreas.
299 However, our transcriptome data provides evidence that both MΦs and ECs are quite attuned to
300 their rapidly changing environment, with integrins and cell adhesion molecules being some of
301 the most dynamically regulated genes in both cell types. Changes in these molecules are likely
302 regulating MΦ recruitment and/or polarization[69–72], which may explain the phenotypic shift that
303 happens between MΦ recruitment (occurring rapidly in response to VEGF-A) and the
304 appearance of β cell proliferation (during VEGF-A normalization).

305 It is also possible that β cells undergo intrinsic changes heightening their sensitivity to
306 extracellular signals, supported by the observation that ECs and MΦs increase expression of
307 several growth factors known to promote β cell proliferation (IGF-1, PDGF, and CTGF)[37,73–75]
308 while β cells simultaneously upregulate expression of corresponding receptors (*Igf1r*, *Pdgfr*).

309 Signaling cascades activated by integrins and growth factors exhibit extensive downstream
310 crosstalk and protein activity that makes it difficult to determine pathway activation status based
311 solely on gene expression. Nonetheless, we did observe transcriptional changes to components
312 of the PI3K/Akt, PLC, and MAPK pathways, as well as upregulation of transcription factors
313 regulated by the MAPK pathway[34–37] suggesting that the cell-cell and cell-ECM interactions may
314 converge on the activation of these pathways leading to β cell proliferation. We therefore
315 propose a model in which coordination of growth factors – whose bioavailability is likely
316 modulated by ECs and MΦs – together with increased integrin signaling promotes activation of
317 pro-proliferative pathways in surviving β cells during VEGF-A normalization to ultimately restore
318 β cell mass (**Figure 6**).

319 Recognizing the key role of cellular and extracellular components of the islet microenvironment
320 on β cell development, function, and homeostasis is critical to further our understanding of
321 signals regulating adult β cell proliferation. Islet microenvironmental signaling in the βVEGF-A
322 system promotes human β cell proliferation[1], which prompted us to develop new strategies to
323 disentangle the roles of various microenvironmental components in this regenerative process.
324 However, moving forward it will be important to further explore the mechanisms and
325 combination of specific cytokines, growth factors, and other microenvironmental signals that
326 activate and regulate relevant mitogenic signaling pathways in human β cells. Overall, these
327 studies highlight the importance of developing innovative approaches to examine β cells *in vivo*
328 in order to more completely understand the complex microenvironmental factors regulating β
329 cell function and regeneration.

METHODS

Mouse Models

All animal studies were approved by the Institutional Animal Care and Use Committee at Vanderbilt University Medical Center, and animals were kept in facilities monitored by the Vanderbilt University Division of Animal Care on a 12 hour light/12 hour dark schedule with unrestricted access to standard chow and water. Mouse models and abbreviations used to describe them are summarized in **Table S2**.

RIP-rtTA; TetO-VEGF (βVEGF-A) mice. The original bitransgenic mice with doxycycline (Dox)-inducible β-cell-specific overexpression of human VEGF-A_{165} (abbreviated βVEGF-A) were generated by crossing RIP-rtTA male mice and TetO-VEGF female mice, both on a C57BL/6 background[76–80]. These mice were generously provided by Dr. Shimon Efrat of Tel Aviv University and Dr. Peter Campochiaro of Johns Hopkins University, respectively. In this βVEGF-A model the rat *Ins2* promoter drives expression of the tetracycline-responsive rtTA transactivator specifically in pancreatic β cells. Upon exposure to Dox, the rtTA transactivator binds the tetracycline operator (*TetO*), driving expression of human VEGF-A_{165} in β-cells. Details of Dox preparation and administration are included below.

Cd5-CreER; VEGFR2$^{fl/fl}$ (VEGFR2$^{i\Delta EC}$) mice. Mice with Tamoxifen (Tm)-inducible EC-specific knockout of VEGFR2 (abbreviated VEGFR2$^{i\Delta EC}$) were generated by crossing Cd5-CreER male mice and VEGFR2$^{fl/fl}$ female mice (see **Table S3**, crosses A1-A2). Heterozygous VEGFR2$^{fl/wt}$ mice on a C57BL/6 background were obtained from Jackson Laboratories (stock #018977) and bred to create a homozygous VEGFR2$^{fl/fl}$ line. Frozen sperm from the Cd5-CreER line[26] was generously provided by Dr. Yoshiaki Kubota of Keio University, and *in vitro* fertilization (IVF) was performed by the Vanderbilt Genome Editing Resource using female C57BL/6 mice (Jackson Laboratories, stock #000664). In the VEGFR2$^{i\Delta EC}$ model *loxP* sites were inserted flanking VEGFR2 exon 3, and the *Cdh5* (*VE-cadherin*) promoter drives expression of Tm-inducible Cre recombinase in vascular ECs. Upon exposure to Tm, Cre recombinase translocates to the nucleus, excising VEGFR2 exon 3 through Cre-*loxP* recombination and subsequently preventing VEGFR2 expression in ECs. Details of Tm preparation and administration are described below.

βVEGF-A; VEGFR2$^{i\Delta EC}$ mice. To generate an inducible model of EC-specific knockdown of VEGFR2 in βVEGF-A mice, Cd5-CreER and VEGFR2$^{fl/fl}$ mice were crossed with RIP-rtTA and

360 TetO-VEGF transgenic mice as outlined in **Table S3**. The final cross produced both βVEGF-A;
361 VEGFR2$^{i\Delta EC}$ mice as well as Cre-negative sibling controls (βVEGF-A; VEGFR2$^{fl/fl}$). Due to the
362 inefficient induction of VEGF-A in female mice (the single copy of the *TetO* transgene is subject
363 to X chromosome inactivation), only male mice were used for experiments.

364 ***βVEGF-A; MIP-GFP mice.*** To enable fluorescence-activated cell sorting (FACS) of pancreatic β
365 cells from βVEGF-A mice, a transgene was separately introduced into the βVEGF-A mouse
366 model by crossing MIP-GFP mice on a C57BL/6 background[81] (Jackson Laboratories, stock
367 #006864) with RIP-rtTA and Tet-O-VEGF-A mice (abbreviated βVEGF-A; MIP-GFP). In these
368 mice, the mouse *Ins1* promoter drives green fluorescent protein (GFP) expression in β cells.

369 ***DNA extraction and genotyping*.** Mouse models used in our breeding schemes were
370 maintained by genotyping using the primers and PCR conditions listed in **Table S4**. DNA was
371 extracted and PCR reactions were performed with tail snips from mice as described previously[1].
372 Thermal cycler conditions listed in **Table S4** were used to amplify DNA before resolving on
373 agarose gels with 100 ng/ml ethidium bromide in 1X Tris/Borate/EDTA (TBE) buffer as
374 indicated.

375 ***Compound preparation and administration.*** VEGF-A transgene expression was activated in
376 βVEGF-A mice by Dox administration (5 mg/ml) in light-protected drinking water containing 1%
377 Splenda® for a period of 3-7 days. VEGFR2 knockdown was induced in VEGFR2$^{i\Delta EC}$ mice by
378 subcutaneous injection of 4 mg Tm (20 mg/ml; 200 µl). Tm (20 mg/ml) was prepared fresh in
379 filter-sterilized corn oil the day before each injection and allowed to dissolve overnight on a
380 shaker at room temperature, protected from light. Vetbond tissue adhesive (3M) was used to
381 seal injection sites to prevent oil leakage. Clodronate-mediated macrophage depletion in
382 βVEGF-A mice was accomplished by injecting 150-200 µl clodronate liposomes (5 mg/ml;
383 Clodrosome) retro-orbitally every other day for a 1-2 week period (4-8 total injections).
384 Liposome injections began one day before Dox administration and continued for 1 week after in
385 mice harvested at later time points. Control liposomes with the same lipid composition
386 (Clodrosome) were administered to βVEGF-A mice using the same route, volume, and
387 schedule. Mice receiving liposome injections were supplemented with Transgenic Dough Diet
388 (21.2% protein, 12.4% fat, 46.5% carbohydrate; BioServ) throughout the course of the
389 experiment.

390 ***Glucose measurements.*** Random (non-fasted) plasma glucose levels were measuring by
391 obtaining whole blood from nicked tail veins using an Accu-chek glucose meter (Roche
392 Diagnostics) calibrated according to the manufacturer's instructions.

393 **Tissue Collection and Fixation**

394 Mouse pancreata were collected from anesthetized mice prior to cervical dislocation. Organs
395 were washed in ice-cold 10 mM phosphate buffered saline (PBS), then fat and other excess
396 tissue was removed before pancreata were weighed and processed. Fixation was performed in
397 0.1 M PBS containing 4% paraformaldehyde (Electron Microscopy Sciences) for 2-3 hours on
398 ice with mild agitation, then organs were washed in four changes of 0.1 M PBS over 2 hours
399 and equilibrated in 30% sucrose/0.01 M PBS overnight. After blotting to remove excess
400 sucrose, tissues were mounted in Tissue Tek cryomolds filled with Tissue-Plus Optimal Cutting
401 Temperature (OCT) compound (VWR Scientific Products). Tissue molds were placed on dry ice
402 until the OCT was set, then stored at -80°C. Tissues were sectioned from 5-10 µm thick on a
403 Leica CM1950 cryostat (Leica) and these cryosections were attached to Superfrost Plus Gold
404 slides (ThermoFischer Scientific).

405 **Immunohistochemistry, Imaging, and Analysis**

406 Immunohistochemical analysis was performed on serial 8-10 µm pancreatic cryosections as
407 described previously[1,18]. Briefly, tissue permeabilization was conducted using 0.2% Triton-X in
408 10nM PBS and blocking using 5% normal donkey serum in 10mM. Primary and secondary
409 antibody incubations (listed in **Table S5**) were performed in buffer with 0.1% Triton-X and 1%
410 BSA and nuclei were counterstained with DAPI. Slides were mounted using SlowFade Gold
411 antifade reagent (Invitrogen Molecular Probes) and sealed with fingernail polish prior to imaging.

412 Digital images were acquired with a Leica DMI6000B fluorescence microscope equipped with a
413 Leica DFC360FX digital camera (Leica), a laser scanning confocal microscope (Zeiss LSM510
414 META or LSM880, Carl Zeiss), and a ScanScope FL (Aperio). Image analysis was performed
415 using MetaMorph 7.7 software (Molecular Devices), ImageScope software (Aperio), or HALO
416 software (Indica Labs).

417 For analysis of islet composition, images of entire pancreatic sections were captured at 20x
418 magnification using a ScanScope FL system. Islet area was annotated manually based on
419 insulin staining, and HALO algorithms were used to calculate area of β cells (Insulin$^+$), ECs

420 (CD31$^+$), and MΦs (Iba1$^+$). For β cell proliferation, cells were deemed positive for Ki67 only
421 when at least 75% of the nucleus was surrounded by insulin$^+$ cytoplasm.

422 **Flow Cytometry and Cell Sorting**

423 Flow analysis and sorting was performed in collaboration with the Vanderbilt Flow Cytometry
424 Core. Peripheral blood (50-100 µl) was collected from the retro-orbital sinus of βVEGF-A mice
425 using heparinized capillary tubes 24 hours after beginning liposome injections to evaluate
426 depletion of circulating monocytes. Blood was incubated for 3-5 minutes at 37°C with 1 ml
427 warmed, filter-sterilized erythrocyte lysis buffer (8.26 g ammonium chloride, 1 g potassium
428 bicarbonate, and 0.38 g EDTA in 1 L Milli-Q water). Cells were pelleted by centrifuging at 1800
429 rpm for 2-3 minutes at 4°C and supernatant discarded. Incubation with erythrocyte lysis buffer
430 was repeated, and then cells were washed with 1 ml FACS buffer (2 mM EDTA and 2% FBS in
431 10 mM PBS) prior to antibody incubation. Blood from WT mice was collected for antibody
432 compensation controls.

433 Isolated islets from βVEGF-A; MIP-GFP mice handpicked in Clonetics EGM MV Microvascular
434 Endothelial Cell Growth Medium (Lonza) were washed 3 times with 2 mM EDTA in 10 mM PBS
435 and then dispersed by incubating with Accutase (Innovative Cell Technologies) at 37°C for 10
436 minutes with constant pipetting. Accutase was quenched with EGM MV media, and then islet
437 cells were washed twice with the same media and counted using a hemocytometer prior to
438 antibody incubation. Anti-rat Ig, κ CompBead Plus Compensation Particles (BD Biosciences)
439 and EasyComp Fluorescent Particles, GFP (Spherotech) were used as single color
440 compensation controls for islet cell sorts.

441 Peripheral blood and islet cells prepared as described above, and anti-rat Ig compensation
442 particles were incubated for 15-20 minutes at 4°C with fluorophore-conjugated antibodies in
443 FACS buffer followed by one wash with FACS buffer. All antibodies for flow cytometry and their
444 working dilutions are listed in **Table S5**. Prior to analysis or sorting, either propidium iodide (0.05
445 µg/100,000 cells; Invitrogen Molecular Probes) or DAPI (0.25 µg/1,000,000 cells; Invitrogen
446 Molecular Probes) was added to samples for non-viable cell exclusion. Flow analysis was
447 performed using an LSRFortessa cell analyzer (BD Biosciences) and a FACSAria III cell sorter
448 (BD Biosciences) was used for FACS. Analysis of flow cytometry data was completed using
449 FlowJo 7.6.5 (Tree Star).

450 **RNA Isolation, Sequencing, and Analysis**

451 Sorted islet-derived cells (8,000-400,000/sample) were added to 200-400 µl lysis/binding
452 solution in the RNAqueous micro-scale phenol-free total RNA isolation kit (Ambion). Trace
453 contaminating DNA was removed with TURBO DNA-free (Ambion). RNA quality control
454 quantification was performed using a Qubit Fluorometer (Invitrogen, Carlsbad, CA) and an
455 Agilent 2100 Bioanalyzer. All RNA samples had an RNA integrity number (RIN) ≥5.0. RNA was
456 amplified using the Ovation system (NuGen Technologies) according to standard protocol.
457 Amplified cDNA was sheared to target 300bp fragment size and libraries were prepared using
458 NEBNext DNA Library Prep (New England BioLabs). 50bp Paired End (PE) sequencing was
459 performed on an Illumina HiSeq 2500 using traditional methods[82,83]. Raw reads were mapped to
460 the reference mouse genome mm9 using TopHat v2.0[84] and aligned reads were then imported
461 onto the Avadis NGS analysis platform (Strand Scientific). Transcript abundance was quantified
462 using the TMM (Trimmed Mean of M-values) algorithm[85,86]. Samples were compared by
463 principle component analysis (PCA) and hierarchal clustering analysis. A minimum expression
464 cutoff (normalized expression ≥20 at one or more time points) was applied before determining
465 differential expression between samples, which was calculated on the basis of fold change
466 (cutoff ≥2 or ≤-2) with p-values estimated by z-score calculations (cutoff 0.05) as determined by
467 the Benjamini Hochberg false discovery rate (FDR) method[87]. Differentially expressed genes
468 were further analyzed through Ingenuity Pathway Analysis (IPA, Qiagen) and Gene Ontology
469 (GO) analysis using DAVID[88]. RNA quality control, amplification, sequencing, and analysis were
470 performed in collaboration with the Genomic Services Laboratory at HudsonAlpha Institute for
471 Biotechnology.

472 **Statistical Analysis**

473 Prism software (GraphPad) was used to perform all statistical analyses for
474 immunohistochemistry. In all experiments manipulating MΦs and ECs, control and experimental
475 groups were compared at each time point using an unpaired t test. For analysis of proliferative
476 ECs, unpaired t tests were also used to compare baseline (No Dox) and VEGF-A induction (3d
477 Dox) time points within each group. For analysis of quiescent ECs, a one-way analysis of
478 variance (ANOVA) was used to analyze time points within each group, followed by Tukey's
479 multiple comparison test to compare each time point with baseline (No Dox). Unless otherwise
480 noted, data are expressed as mean + standard error of mean (SEM). Statistical analysis of
481 RNA-sequencing data is described above (see RNA Isolation, Sequencing, and Analysis).

482 **AUTHOR CONTRIBUTIONS**

483 Conceptualization, D.C.S., K.I.A., M.B., and A.C.P.; Methodology, D.C.S., K.I.A., M.B., and
484 A.C.P.; Investigation, D.C.S., K.I.A., T.M.R., A.H., Z.K., R.A., G.P., R.J., and M.B.; Formal
485 Analysis, N.P.; Writing – Original Draft, D.C.S., M.B., and A.C.P.; Writing – Review & Editing, all
486 authors; Funding Acquisition, A.C.P.; Supervision, A.C.P., M.B., and S.E.L.

487 **ACKNOWLEDGEMENTS**

488 We thank Drs. Y. Kubota, S. Efrat, P. Campochiaro, and M. Gannon for providing mice. We are
489 grateful to Drs. A. Pozzi, A. Hatzopoulos, D. Jacobson, R. Stein, P. Kendall, J. Thomas, V.
490 Babaev, P. Young, and Y. Dor for helpful discussions. This work was supported by grants from
491 the Department of Veterans Affairs, the JDRF, the NIH (DK106755, DK89572, DK66636,
492 DK69603, DK63439, DK62641, DK72473, DK94199, DK68764, DK97829, DK11232,
493 DK117147, DK104211), and the Vanderbilt Diabetes Research and Training Center (DK20593).
494 Islet isolation was performed in the Vanderbilt Islet Procurement and Analysis Core (DK20593).
495 Image acquisition was performed in part through use of the Vanderbilt Cell Imaging Shared
496 Resource (CA68485, DK20593, DK58404, DK59637, EY08126) and Vanderbilt Islet
497 Procurement and Analysis Core (DK20593). Flow cytometry was performed in the Vanderbilt
498 Flow Cytometry Shared Resource (P30 CA68485, DK058404). Cd5-CreER mouse line
499 rederivation was performed by the Vanderbilt Genome Editing Resource of the Center for Stem
500 Cell Biology (CA68485, DK20593).

REFERENCES

1. Brissova, M; Aamodt, K; Brahmachary, P; Prasad, N; Hong, J-Y; Dai, C; Mellati, M; Shostak, A; Poffenberger, G; Aramandla, R; et al. Islet Microenvironment, Modulated by Vascular Endothelial Growth Factor-A Signaling, Promotes β Cell Regeneration. *Cell Metab* **2014**, *19* (3), 498 511. https://doi.org/10.1016/j.cmet.2014.02.001.

2. Tsunawaki, S; Sporn, M; Ding, A; Nathan, C. Deactivation of Macrophages by Transforming Growth Factor-β. *Nature* **1988**, *334* (6179), 260–262. https://doi.org/10.1038/334260a0.

3. Ricardo, SD; Goor, H van; Eddy, AA. Macrophage Diversity in Renal Injury and Repair. *J Clin Invest* **2008**, *118* (11), 3522 3530. https://doi.org/10.1172/jci36150.

4. He, H; Xu, J; Warren, CM; Duan, D; Li, X; Wu, L; Iruela-Arispe, ML. Endothelial Cells Provide an Instructive Niche for the Differentiation and Functional Polarization of M2-like Macrophages. *Blood* **2012**, *120* (15), 3152–3162. https://doi.org/10.1182/blood-2012-04-422758.

5. Sica, A; Mantovani, A. Macrophage Plasticity and Polarization: In Vivo Veritas. *J Clin Invest* **2012**, *122* (3), 787 795. https://doi.org/10.1172/jci59643.

6. Meier, JJ; Bhushan, A; Butler, AE; Rizza, RA; Butler, PC. Sustained Beta Cell Apoptosis in Patients with Long-Standing Type 1 Diabetes: Indirect Evidence for Islet Regeneration? *Diabetologia* **2005**, *48* (11), 2221–2228. https://doi.org/10.1007/s00125-005-1949-2.

7. Campbell-Thompson, ML; Atkinson, MA; Butler, AE; Chapman, NM; Frisk, G; Gianani, R; Giepmans, BN; Herrath, MG von; Hyöty, H; Kay, TW; et al. The Diagnosis of Insulitis in Human Type 1 Diabetes. *Diabetologia* **2013**, *56* (11), 2541–2543. https://doi.org/10.1007/s00125-013-3043-5.

8. Halban, PA; Polonsky, KS; Bowden, DW; Hawkins, MA; Ling, C; Mather, KJ; Powers, AC; Rhodes, CJ; Sussel, L; Weir, GC. β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment. *Diabetes Care* **2014**, *37* (6), 1751–1758. https://doi.org/10.2337/dc14-0396.

9. Banaei-Bouchareb, L; Gouon-Evans, V; Samara-Boustani, D; Castellotti, MC; Czernichow, P; Pollard, JW; Polak, M. Insulin Cell Mass Is Altered in Csf1op/Csf1op Macrophage-Deficient Mice. *J Leukocyte Biol* **2004**, *76* (2), 359 367. https://doi.org/10.1189/jlb.1103591.

10. Mussar, K; Tucker, A; McLennan, L; Gearhart, A; Jimenez-Caliani, AJ; Cirulli, V; Crisa, L. Macrophage/Epithelium Cross-Talk Regulates Cell Cycle Progression and Migration in Pancreatic Progenitors. *Plos One* **2014**, *9* (2), e89492. https://doi.org/10.1371/journal.pone.0089492.

11. Xiao, X; Gaffar, I; Guo, P; Wiersch, J; Fischbach, S; Peirish, L; Song, Z; El-Gohary, Y; Prasadan, K; Shiota, C; et al. M2 Macrophages Promote Beta-Cell Proliferation by up-Regulation of SMAD7. *Proc National Acad Sci* **2014**, *111* (13), E1211 20. https://doi.org/10.1073/pnas.1321347111.

12. Criscimanna, A; Coudriet, GM; Gittes, GK; Piganelli, JD; Esni, F. Activated Macrophages Create Lineage-Specific Microenvironments for Pancreatic Acinar- and β-Cell Regeneration in Mice. *Gastroenterology* **2014**, *147* (5), 1106 18.e11. https://doi.org/10.1053/j.gastro.2014.08.008.

13. Ding, B-S; Nolan, DJ; Butler, JM; James, D; Babazadeh, AO; Rosenwaks, Z; Mittal, V; Kobayashi, H; Shido, K; Lyden, D; et al. Inductive Angiocrine Signals from Sinusoidal Endothelium Are Required for Liver Regeneration. *Nature* **2010**, *468* (7321), 310 315. https://doi.org/10.1038/nature09493.

14. Butler, JM; Nolan, DJ; Vertes, EL; Varnum-Finney, B; Kobayashi, H; Hooper, AT; Seandel, M; Shido, K; White, IA; Kobayashi, M; et al. Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells. *Cell Stem Cell* **2010**, *6* (3), 251–264. https://doi.org/10.1016/j.stem.2010.02.001.

15. Butler, JM; Kobayashi, H; Rafii, S. Instructive Role of the Vascular Niche in Promoting Tumour Growth and Tissue Repair by Angiocrine Factors. *Nat Rev Cancer* **2010**, *10* (2), 138 146. https://doi.org/10.1038/nrc2791.

16. Ding, B-S; Nolan, DJ; Guo, P; Babazadeh, AO; Cao, Z; Rosenwaks, Z; Crystal, RG; Simons, M; Sato, TN; Worgall, S; et al. Endothelial-Derived Angiocrine Signals Induce and Sustain Regenerative Lung Alveolarization. *Cell* **2011**, *147* (3), 539 553. https://doi.org/10.1016/j.cell.2011.10.003.

17. Cai, Q; Brissova, M; Reinert, RB; Pan, FC; Brahmachary, P; Jeansson, M; Shostak, A; Radhika, A; Poffenberger, G; Quaggin, SE; et al. Enhanced Expression of VEGF-A in β Cells Increases Endothelial Cell Number but Impairs Islet Morphogenesis and β Cell Proliferation. *Dev Biol* **2012**, *367* (1), 40 54. https://doi.org/10.1016/j.ydbio.2012.04.022.

18. Reinert, RB; Brissova, M; Shostak, A; Pan, FC; Poffenberger, G; Cai, Q; Hundemer, GL; Kantz, J; Thompson, CS; Dai, C; et al. Vascular Endothelial Growth Factor-A and Islet Vascularization Are Necessary in Developing, but Not Adult, Pancreatic Islets. *Diabetes* **2013**, *62* (12), 4154–4164. https://doi.org/10.2337/db13-0071.

19. Sand, FW; Hörnblad, A; Johansson, JK; Lorén, C; Edsbagge, J; Ståhlberg, A; Magenheim, J; Ilovich, O; Mishani, E; Dor, Y; et al. Growth-Limiting Role of Endothelial Cells in Endoderm Development. *Dev Biol* **2011**, *352* (2), 267 277. https://doi.org/10.1016/j.ydbio.2011.01.026.

20. Hammar, E; Parnaud, G; Bosco, D; Perriraz, N; Maedler, K; Donath, M; Rouiller, DG; Halban, PA. Extracellular Matrix Protects Pancreatic β-Cells Against Apoptosis Role of Short- and Long-Term Signaling Pathways. *Diabetes* **2004**, *53* (8), 2034–2041. https://doi.org/10.2337/diabetes.53.8.2034.

21. Nikolova, G; Jabs, N; Konstantinova, I; Domogatskaya, A; Tryggvason, K; Sorokin, L; Fässler, R; Gu, G; Gerber, H-P; Ferrara, N; et al. The Vascular Basement Membrane: A Niche for Insulin Gene Expression and Beta Cell Proliferation. *Dev Cell* **2006**, *10* (3), 397 405. https://doi.org/10.1016/j.devcel.2006.01.015.

22. Diaferia, GR; Jimenez-Caliani, AJ; Ranjitkar, P; Yang, W; Hardiman, G; Rhodes, CJ; Crisa, L; Cirulli, V. B1 Integrin Is a Crucial Regulator of Pancreatic β-Cell Expansion. *Development* **2013**, *140* (16), 3360–3372. https://doi.org/10.1242/dev.098533.

23. Aamodt, KI; Powers, AC. Signals in the Pancreatic Islet Microenvironment Influence β-Cell Proliferation. *Diabetes Obes Metabolism* **2017**, *19* (S1), 124–136. https://doi.org/10.1111/dom.13031.

24. Göthert, JR; Gustin, SE; Eekelen, JAM van; Schmidt, U; Hall, MA; Jane, SM; Green, AR; Göttgens, B; Izon, DJ; Begley, CG. Genetically Tagging Endothelial Cells in Vivo: Bone Marrow-Derived Cells Do Not Contribute to Tumor Endothelium. *Blood* **2004**, *104* (6), 1769–1777. https://doi.org/10.1182/blood-2003-11-3952.

25. Zambrowicz, BP; Imamoto, A; Fiering, S; Herzenberg, LA; Kerr, WG; Soriano, P. Disruption of Overlapping Transcripts in the ROSA Geo 26 Gene Trap Strain Leads to Widespread Expression of -Galactosidase in Mouse Embryos and Hematopoietic Cells. *Proc National Acad Sci* **1997**, *94* (8), 3789–3794. https://doi.org/10.1073/pnas.94.8.3789.

26. Okabe, K; Kobayashi, S; Yamada, T; Kurihara, T; Tai-Nagara, I; Miyamoto, T; Mukouyama, Y; Sato, TN; Suda, T; Ema, M; et al. Neurons Limit Angiogenesis by Titrating VEGF in Retina. *Cell* **2014**, *159* (3), 584 596. https://doi.org/10.1016/j.cell.2014.09.025.

27. Carboneau, BA; Le, TDV; Dunn, JC; Gannon, M. Unexpected Effects of the MIP-CreER Transgene and Tamoxifen on β-Cell Growth in C57Bl6/J Male Mice. *Physiological Reports* **2016**, *4* (18), e12863. https://doi.org/10.14814/phy2.12863.

28. Luttun, A; Tjwa, M; Moons, L; Wu, Y; Angelillo-Scherrer, A; Liao, F; Nagy, JA; Hooper, A; Priller, J; Klerck, BD; et al. Revascularization of Ischemic Tissues by PlGF Treatment, and Inhibition of Tumor Angiogenesis, Arthritis and Atherosclerosis by Anti-Flt1. *Nat Med* **2002**, *8* (8), 831–840. https://doi.org/10.1038/nm731.

29. Takahashi, H; Shibuya, M. The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor System and Its Role under Physiological and Pathological Conditions. *Clin Sci* **2005**, *109* (3), 227–241. https://doi.org/10.1042/cs20040370.

30. Calderon, B; Carrero, JA; Ferris, ST; Sojka, DK; Moore, L; Epelman, S; Murphy, KM; Yokoyama, WM; Randolph, GJ; Unanue, ER. The Pancreas Anatomy Conditions the Origin and Properties of Resident Macrophages. *J Exp Medicine* **2015**, *212* (10), 1497 1512. https://doi.org/10.1084/jem.20150496.

31. Weitz, JR; Makhmutova, M; Almaça, J; Stertmann, J; Aamodt, K; Brissova, M; Speier, S; Rodriguez-Diaz, R; Caicedo, A. Mouse Pancreatic Islet Macrophages Use Locally Released ATP to Monitor Beta Cell Activity. *Diabetologia* **2018**, *61* (1), 182–192. https://doi.org/10.1007/s00125-017-4416-y.

32. Kragl, M; Lammert, E. The Islets of Langerhans; The Islets of Langerhans; Springer Netherlands, 2010; Vol. 654, pp 217–234. https://doi.org/10.1007/978-90-481-3271-3_10.

33. Bogdani, M. Thinking Outside the Cell: A Key Role for Hyaluronan in the Pathogenesis of Human Type 1 Diabetes. *Diabetes* **2016**, *65* (8), 2105–2114. https://doi.org/10.2337/db15-1750.

34. Schlaepfer, DD; Hanks, SK; Hunter, T; Geer, P van der. Integrin-Mediated Signal Transduction Linked to Ras Pathway by GRB2 Binding to Focal Adhesion Kinase. *Nature* **1994**, *372* (6508), 786–791. https://doi.org/10.1038/372786a0.

35. Foulds, CE; Nelson, ML; Blaszczak, AG; Graves, BJ. Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/P300 Recruitment†. *Mol Cell Biol* **2004**, *24* (24), 10954–10964. https://doi.org/10.1128/mcb.24.24.10954-10964.2004.

36. Carlson, SM; Chouinard, CR; Labadorf, A; Lam, CJ; Schmelzle, K; Fraenkel, E; White, FM. Large-Scale Discovery of ERK2 Substrates Identifies ERK-Mediated Transcriptional Regulation by ETV3. *Sci Signal* **2011**, *4* (196), rs11–rs11. https://doi.org/10.1126/scisignal.2002010.

37. Chen, H; Gu, X; Liu, Y; Wang, J; Wirt, SE; Bottino, R; Schorle, H; Sage, J; Kim, SK. PDGF Signalling Controls Age-Dependent Proliferation in Pancreatic β-Cells. *Nature* **2011**, *478* (7369), 349 355. https://doi.org/10.1038/nature10502.

38. Fiaschi-Taesch, N; Bigatel, TA; Sicari, B; Takane, KK; Salim, F; Velazquez-Garcia, S; Harb, G; Selk, K; Cozar-Castellano, I; Stewart, AF. Survey of the Human Pancreatic β-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human β-Cell Replication and Function In Vivo. *Diabetes* **2009**, *58* (4), 882–893. https://doi.org/10.2337/db08-0631.

39. Zhang, H; Zhang, J; Pope, CF; Crawford, LA; Vasavada, RC; Jagasia, SM; Gannon, M. Gestational Diabetes Mellitus Resulting From Impaired β-Cell Compensation in the Absence of FoxM1, a Novel Downstream Effector of Placental Lactogen. *Diabetes* **2009**, *59* (1), 143–152. https://doi.org/10.2337/db09-0050.

40. Karnik, SK; Hughes, CM; Gu, X; Rozenblatt-Rosen, O; McLean, GW; Xiong, Y; Meyerson, M; Kim, SK. Menin Regulates Pancreatic Islet Growth by Promoting Histone Methylation and Expression of Genes Encoding P27Kip1 and P18INK4c. *P Natl Acad Sci Usa* **2005**, *102* (41), 14659 14664. https://doi.org/10.1073/pnas.0503484102.

41. Shi, C; Pamer, EG. Monocyte Recruitment during Infection and Inflammation. *Nat Rev Immunol* **2011**, *11* (11), 762–774. https://doi.org/10.1038/nri3070.

42. Grunnet, LG; Aikin, R; Tonnesen, MF; Paraskevas, S; Blaabjerg, L; Størling, J; Rosenberg, L; Billestrup, N; Maysinger, D; Mandrup-Poulsen, T. Proinflammatory Cytokines Activate the Intrinsic Apoptotic Pathway in β-Cells. *Diabetes* **2009**, *58* (8), 1807–1815. https://doi.org/10.2337/db08-0178.

43. Jourdan, T; Godlewski, G; Cinar, R; Bertola, A; Szanda, G; Liu, J; Tam, J; Han, T; Mukhopadhyay, B; Skarulis, MC; et al. Activation of the Nlrp3 Inflammasome in Infiltrating Macrophages by Endocannabinoids Mediates Beta Cell Loss in Type 2 Diabetes. *Nat Med* **2013**, *19* (9), 1132–1140. https://doi.org/10.1038/nm.3265.

44. David, S; Kroner, A. Repertoire of Microglial and Macrophage Responses after Spinal Cord Injury. *Nat Rev Neurosci* **2011**, *12* (7), 388–399. https://doi.org/10.1038/nrn3053.

45. Zizzo, G; Hilliard, BA; Monestier, M; Cohen, PL. Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction. *J Immunol* **2012**, *189* (7), 3508–3520. https://doi.org/10.4049/jimmunol.1200662.

46. Naito, Y; Takagi, T; Higashimura, Y. Heme Oxygenase-1 and Anti-Inflammatory M2 Macrophages. *Arch Biochem Biophys* **2014**, *564*, 83 88. https://doi.org/10.1016/j.abb.2014.09.005.

47. Tessem, JS; Jensen, JN; Pelli, H; Dai, X-M; Zong, X-H; Stanley, ER; Jensen, J; DeGregori, J. Critical Roles for Macrophages in Islet Angiogenesis and Maintenance During Pancreatic Degeneration. *Diabetes* **2008**, *57* (6), 1605–1617. https://doi.org/10.2337/db07-1577.

48. Lammert, E. Induction of Pancreatic Differentiation by Signals from Blood Vessels. *Science* **2001**, *294* (5542), 564 567. https://doi.org/10.1126/science.1064344.

49. Lammert, E; Cleaver, O; Melton, D. Role of Endothelial Cells in Early Pancreas and Liver Development. *Mech Develop* **2003**, *120* (1), 59–64. https://doi.org/10.1016/s0925-4773(02)00332-5.

50. Yoshitomi, H; Zaret, KS. Endothelial Cell Interactions Initiate Dorsal Pancreas Development by Selectively Inducing the Transcription Factor Ptf1a. *Development* **2004**, *131* (4), 807–817. https://doi.org/10.1242/dev.00960.

51. Zhang, N; Richter, A; Suriawinata, J; Harbaran, S; Altomonte, J; Cong, L; Zhang, H; Song, K; Meseck, M; Bromberg, J; et al. Elevated Vascular Endothelial Growth Factor Production in Islets Improves Islet Graft Vascularization. *Diabetes* **2004**, *53* (4), 963 970.

52. Narang, AS; Cheng, K; Henry, J; Zhang, C; Sabek, O; Fraga, D; Kotb, M; Gaber, AO; Mahato, RI. Vascular Endothelial Growth Factor Gene Delivery for Revascularization in Transplanted Human Islets. *Pharmaceut Res* **2004**, *21* (1), 15–25. https://doi.org/10.1023/b:pham.0000012147.52900.b8.

53. Lai, Y; Schneider, D; Kidszun, A; Hauck-Schmalenberger, I; Breier, G; Brandhorst, D; Brandhorst, H; Iken, M; Brendel, MD; Bretzel, RG; et al. Vascular Endothelial Growth Factor Increases Functional Beta-Cell Mass by Improvement of Angiogenesis of Isolated Human and Murine Pancreatic Islets. *Transplantation* **2005**, *79* (11), 1530 1536. https://doi.org/10.1097/01.tp.0000163506.40189.65.

54. Phelps, EA; Templeman, KL; Thulé, PM; García, AJ. Engineered VEGF-Releasing PEG-MAL Hydrogel for Pancreatic Islet Vascularization. *Drug Deliv Transl Re* **2015**, *5* (2), 125 136. https://doi.org/10.1007/s13346-013-0142-2.

55. Weber, LM; Hayda, KN; Anseth, KS. Cell–Matrix Interactions Improve β-Cell Survival and Insulin Secretion in Three-Dimensional Culture. *Tissue Eng Pt A* **2008**, *14* (12), 1959–1968. https://doi.org/10.1089/ten.tea.2007.0238.

56. Cucak, H; Grunnet, LG; Rosendahl, A. Accumulation of M1-like Macrophages in Type 2 Diabetic Islets Is Followed by a Systemic Shift in Macrophage Polarization. *J Leukocyte Biol* **2014**, *95* (1), 149 160. https://doi.org/10.1189/jlb.0213075.

57. Lavin, Y; Winter, D; Blecher-Gonen, R; David, E; Keren-Shaul, H; Merad, M; Jung, S; Amit, I. Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment. *Cell* **2014**, *159* (6), 1312 1326. https://doi.org/10.1016/j.cell.2014.11.018.

58. Stout, RD; Jiang, C; Matta, B; Tietzel, I; Watkins, SK; Suttles, J. Macrophages Sequentially Change Their Functional Phenotype in Response to Changes in Microenvironmental Influences. *J Immunol* **2005**, *175* (1), 342–349. https://doi.org/10.4049/jimmunol.175.1.342.

59. Gassen, NV; Overmeire, EV; Leuckx, G; Heremans, Y; Groef, SD; Cai, Y; Elkrim, Y; Gysemans, C; Stijlemans, B; Casteele, MV de; et al. Macrophage Dynamics Are Regulated by Local Macrophage Proliferation and Monocyte Recruitment in Injured Pancreas. *Eur J Immunol* **2015**, *45* (5), 1482 1493. https://doi.org/10.1002/eji.201445013.

60. Parnaud, G; Hammar, E; Ribaux, P; Donath, MY; Berney, T; Halban, PA. Signaling Pathways Implicated in the Stimulation of β-Cell Proliferation by Extracellular Matrix. *J Clin Endocrinol Metabolism* **2009**, *94* (7), 2672–2672. https://doi.org/10.1210/jcem.94.7.9995.

61. Liu, J; Liu, S; Chen, Y; Zhao, X; Lu, Y; Cheng, J. Functionalized Self-Assembling Peptide Improves INS-1 β-Cell Function and Proliferation via the Integrin/FAK/ERK/Cyclin Pathway. *Int J Nanomed* **2015**, *Volume 10* (1), 3519–3531. https://doi.org/10.2147/ijn.s80502.

62. Peart, J; Li, J; Lee, H; Riopel, M; Feng, Z-C; Wang, R. Critical Role of B1 Integrin in Postnatal Beta-Cell Function and Expansion. *Oncotarget* **2017**, *8* (38), 62939–62952. https://doi.org/10.18632/oncotarget.17969.

63. Mohammed, FF; Pennington, CJ; Kassiri, Z; Rubin, JS; Soloway, PD; Ruther, U; Edwards, DR; Khokha, R. Metalloproteinase Inhibitor TIMP-1 Affects Hepatocyte Cell Cycle via HGF Activation in Murine Liver Regeneration. *Hepatology* **2005**, *41* (4), 857–867. https://doi.org/10.1002/hep.20618.

64. Kveiborg, M; Albrechtsen, R; Couchman, JR; Wewer, UM. Cellular Roles of ADAM12 in Health and Disease. *Int J Biochem Cell Biology* **2008**, *40* (9), 1685–1702. https://doi.org/10.1016/j.biocel.2008.01.025.

65. Apte, SS. A Disintegrin-like and Metalloprotease (Reprolysin-Type) with Thrombospondin Type 1 Motif (ADAMTS) Superfamily: Functions and Mechanisms. *J Biol Chem* **2009**, *284* (46), 31493–31497. https://doi.org/10.1074/jbc.r109.052340.

66. Townsend, SE; Gannon, M. Extracellular Matrix–Associated Factors Play Critical Roles in Regulating Pancreatic β-Cell Proliferation and Survival. *Endocrinology* **2019**, *160* (8), 1885–1894. https://doi.org/10.1210/en.2019-00206.

67. Coudriet, GM; He, J; Trucco, M; Mars, WM; Piganelli, JD. Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases. *Plos One* **2010**, *5* (11), e15384. https://doi.org/10.1371/journal.pone.0015384.

68. Song, I; Patel, O; Himpe, E; Muller, CJF; Bouwens, L. Beta Cell Mass Restoration in Alloxan-Diabetic Mice Treated with EGF and Gastrin. *Plos One* **2015**, *10* (10), e0140148. https://doi.org/10.1371/journal.pone.0140148.

69. Sicari, BM; Dziki, JL; Siu, BF; Medberry, CJ; Dearth, CL; Badylak, SF. The Promotion of a Constructive Macrophage Phenotype by Solubilized Extracellular Matrix. *Biomaterials* **2014**, *35* (30), 8605–8612. https://doi.org/10.1016/j.biomaterials.2014.06.060.

70. Brown, BN; Sicari, BM; Badylak, SF. Rethinking Regenerative Medicine: A Macrophage-Centered Approach. *Front Immunol* **2014**, *5* (8), 510. https://doi.org/10.3389/fimmu.2014.00510.

71. Chen, P; Cescon, M; Zuccolotto, G; Nobbio, L; Colombelli, C; Filaferro, M; Vitale, G; Feltri, ML; Bonaldo, P. Collagen VI Regulates Peripheral Nerve Regeneration by Modulating Macrophage Recruitment and Polarization. *Acta Neuropathol* **2015**, *129* (1), 97 113. https://doi.org/10.1007/s00401-014-1369-9.

72. Kim, H; Cha, J; Jang, M; Kim, P. Hyaluronic Acid-Based Extracellular Matrix Triggers Spontaneous M2-like Polarity of Monocyte/Macrophage. *Biomater Sci-uk* **2019**, *7* (6), 2264–2271. https://doi.org/10.1039/c9bm00155g.

73. Guney, MA; Petersen, CP; Boustani, A; Duncan, MR; Gunasekaran, U; Menon, R; Warfield, C; Grotendorst, GR; Means, AL; Economides, AN; et al. Connective Tissue Growth Factor Acts within Both Endothelial Cells and Beta Cells to Promote Proliferation of Developing Beta Cells. *Proc National Acad Sci* **2011**, *108* (37), 15242 15247. https://doi.org/10.1073/pnas.1100072108.

74. Kulkarni, RN; Mizrachi, E-B; Ocana, AG; Stewart, AF. Human β-Cell Proliferation and Intracellular Signaling Driving in the Dark Without a Road Map. *Diabetes* **2012**, *61* (9), 2205–2213. https://doi.org/10.2337/db12-0018.

75. Riley, KG; Pasek, RC; Maulis, MF; Peek, J; Thorel, F; Brigstock, DR; Herrera, PL; Gannon, M. Connective Tissue Growth Factor Modulates Adult β-Cell Maturity and Proliferation to Promote β-Cell Regeneration in Mice. *Diabetes* **2015**, *64* (4), 1284 1298. https://doi.org/10.2337/db14-1195.

76. Brissova, M; Shostak, A; Shiota, M; Wiebe, PO; Poffenberger, G; Kantz, J; Chen, Z; Carr, C; Jerome, WG; Chen, J; et al. Pancreatic Islet Production of Vascular Endothelial Growth Factor--a Is Essential for Islet Vascularization, Revascularization, and Function. *Diabetes* **2006**, *55* (11), 2974 2985. https://doi.org/10.2337/db06-0690.

77. Nyman, LR; Wells, KS; Head, WS; McCaughey, M; Ford, E; Brissova, M; Piston, DW; Powers, AC. Real-Time, Multidimensional in Vivo Imaging Used to Investigate Blood Flow in Mouse Pancreatic Islets. *J Clin Investigation* **2008**, *118* (11), 3790–3797. https://doi.org/10.1172/jci36209.

78. Efrat, S; Fusco-DeMane, D; Lemberg, H; Emran, O al; Wang, X. Conditional Transformation of a Pancreatic Beta-Cell Line Derived from Transgenic Mice Expressing a Tetracycline-Regulated Oncogene. *Proceedings of the National Academy of Sciences* **1995**, *92* (8), 3576 3580.

79. Milo-Landesman, D; Surana, M; Berkovich, I; Compagni, A; Christofori, G; Fleischer, N; Efrat, S. Correction of Hyperglycemia in Diabetic Mice Transplanted with Reversibly Immortalized Pancreatic Beta Cells Controlled by the Tet-on Regulatory System. *Cell Transplant* **2001**, *10* (7), 645–650. https://doi.org/10.3727/000000001783986422.

80. Ohno-Matsui, K; Hirose, A; Yamamoto, S; Saikia, J; Okamoto, N; Gehlbach, P; Duh, EJ; Hackett, S; Chang, M; Bok, D; et al. Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment. *Am J Pathology* **2002**, *160* (2), 711 719. https://doi.org/10.1016/s0002-9440(10)64891-2.

81. Hara, M; Wang, X; Kawamura, T; Bindokas, VP; Dizon, RF; Alcoser, SY; Magnuson, MA; Bell, GI. Transgenic Mice with Green Fluorescent Protein-Labeled Pancreatic β-Cells. *Am J Physiol-endoc M* **2003**, *284* (1), E177–E183. https://doi.org/10.1152/ajpendo.00321.2002.

82. Mortazavi, A; Williams, BA; McCue, K; Schaeffer, L; Wold, B. Mapping and Quantifying Mammalian Transcriptomes by RNA-Seq. *Nat Methods* **2008**, *5* (7), 621–628. https://doi.org/10.1038/nmeth.1226.

83. Malone, JH; Oliver, B. Microarrays, Deep Sequencing and the True Measure of the Transcriptome. *Bmc Biol* **2011**, *9* (1), 34. https://doi.org/10.1186/1741-7007-9-34.

84. Trapnell, C; Pachter, L; Salzberg, SL. TopHat: Discovering Splice Junctions with RNA-Seq. *Bioinformatics* **2009**, *25* (9), 1105–1111. https://doi.org/10.1093/bioinformatics/btp120.

85. Robinson, MD; Oshlack, A. A Scaling Normalization Method for Differential Expression Analysis of RNA-Seq Data. *Genome Biol* **2010**, *11* (3), R25. https://doi.org/10.1186/gb-2010-11-3-r25.

86. Dillies, M-A; Rau, A; Aubert, J; Hennequet-Antier, C; Jeanmougin, M; Servant, N; Keime, C; Marot, G; Castel, D; Estelle, J; et al. A Comprehensive Evaluation of Normalization Methods for Illumina High-Throughput RNA Sequencing Data Analysis. *Brief Bioinform* **2013**, *14* (6), 671–683. https://doi.org/10.1093/bib/bbs046.

87. Benjamini, Y; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society, Series B Methodological* **1995**, *57*, 289 300.

88. Huang, DW; Sherman, BT; Zheng, X; Yang, J; Imamichi, T; Stephens, R; Lempicki, RA. Extracting Biological Meaning from Large Gene Lists with DAVID. *Curr Protoc Bioinform* **2009**, *Chapter 13* (1), Unit 13.11 13.11.13. https://doi.org/10.1002/0471250953.bi1311s27.

SUPPLEMENTAL FIGURES



Figure S1. Schematic representation of experiments to determine the role of macrophages and endothelial cells in the βVEGF-A mouse model. (A) Clodronate liposomes were used to suppress macrophage (MΦ) infiltration, followed by administration of doxycycline (Dox) to overexpress VEGF-A in β cells. **(B–C)** To modulate endothelial cells (ECs), an inducible EC-specific VEGFR2 knockout mouse model Cd5-CreER; VEGFR2$^{fl/fl}$ (VEGFR2$^{i\Delta EC}$)[26] was bred into the βVEGF-A line. Tamoxifen (Tm) was used to inactivate VEGFR2 in ECs either prior to **(B)** or after **(C)** VEGF-A induction to discern the role of proliferative and quiescent ECs, respectively in the β cell loss and recovery. **(D)** ECs, MΦs, and β cells were isolated from βVEGF-A mice at three time points; introduction of the MIP-GFP transgene facilitated β cell sorting. For additional details, see **Methods**.





Figure S2. Acute ablation of VEGFR2 in endothelial cells does not alter islet vascular homeostasis or β cell proliferation. (A) To inactivate VEGFR2 in endothelial cells (ECs), Cdh5-CreER^{T2}; VEGFR2$^{fl/fl}$ (VEGFR2$^{i\Delta EC}$) mice received treatments (Tx) of corn oil (vehicle) or tamoxifen (Tm; 4mg s.c.) every other day for 5 days. **(B)** Representative images of islet ECs (CD31^{+}) and β cells (Insulin^{+}) in vehicle- and Tm-treated VEGFR2$^{i\Delta EC}$ mice. VEGFR2 expression (red) is virtually undetectable in ECs at 8 or 15 days (d) after initial Tx. Scale bar, 50 μm. **(C–E)** Quantification (mean±SEM) of islet architecture in VEGFR2$^{i\Delta EC}$ mice at 8d post-Tx; each circle represents one animal. Islet capillary density **(C)** and area per islet capillary **(D)** determined by CD31^{+} and Insulin^{+} stain; 138±15 x 10^5 μm^2 total islet area analyzed per animal. **(E)** Basal β cell proliferation rate; 1,892±259 cells counted per animal. Statistics shown in **(C)** and **(E)** reflect unpaired t-tests. **(F)** In both vehicle- and Tm-treated mice, the number of islet capillaries increases proportionately with islet size. Note both axes have a base 2 logarithmic scale.



Figure S3. Effective VEGFR2 inactivation in endothelial cells prevents islet capillary expansion by acute elevation of VEGF-A in the islet microenvironment. (A) To inactivate VEGFR2 in endothelial cells (ECs), βVEGF-A; R2$^{i\Delta EC}$ mice and βVEGF-A; R2$^{fl/fl}$ controls were treated with Tamoxifen (Tm; 4mg s.c.) prior to VEGF-A induction. **(B)** Left panel: induction of VEGFA expression at 3d Dox compared to baseline (No Dox) in βVEGF-A; R2$^{i\Delta EC}$ mice and controls; VEGF-A (red); β cells (Insulin^{+}, blue). Boxes indicate regions enlarged in insets. Right panel: inactivation of VEGFR2 expression in ECs at baseline and 3d Dox; VEGFR2 (red), ECs (CD31^{+}, green); β cells (Insulin^{+}, blue). Scale bars, 50 μm; inset, 10 μm.



Figure S4. Effects of VEGF-A induction and VEGFR2 inactivation during β cell recovery. **(A)** To inactivate VEGFR2 in endothelial cells (ECs) during β cell recovery, control (βVEGF-A; VEGFR2$^{fl/fl}$) and VEGFR2$^{i\Delta EC}$ (βVEGF-A; VEGFR2$^{i\Delta EC}$) mice received Tamoxifen (Tm; 4mg s.c.) after 7 days (d) of Dox withdrawal (WD). **(B)** Expression of VEGF-A in β cells and (**C**) VEGFR2 in ECs at 7d WD and 9d WD. Boxes show regions enlarged in insets; arrowheads point to extracellular VEGF-A staining. **(D)** Intra-islet M2-like macrophages (MΦs, CD206^{+} Iba1^{+}) were present in both control and VEGFR2$^{i\Delta EC}$ mice before and after Tm treatment. Approximate islet area is outlined; boxes show regions enlarged in insets with insulin channel (blue) removed. Scale bars in **(B–D)** are 50 μm; insets, 10 μm.



Figure S5. Transcriptome analysis demonstrates unique gene expression profiles in β cells, endothelial cells and macrophages purified from islets during the period of β cell loss and recovery. (A–B) Dispersed islet cells from βVEGF-A; MIP-GFP mice were immunolabeled with fluorophore-conjugated anti-CD31 and anti-CD11b antibodies to separate endothelial cell (EC) and macrophage (MΦ) populations, respectively. GFP⁺ β cells were sorted from the CD31⁻ CD11b⁻ population. **(C)** Principal component analysis (PCA) plot shows the clustering of samples from sorted β cells (blue), ECs (green), and MΦs (red) at No Dox, 1wk Dox, and 1wk WD; n=3-5 samples per time point as listed in Key. Islets from multiple mice were pooled to obtain adequate cells for each sample. **(D)** Pairwise correlation between all samples at all time points based on the Spearman correlation coefficient, which ranks and quantifies the degree of similarity between each pair of samples (perfect correlation=1; green). **(E)** Total number of genes for each cell type significantly up- or down-regulated (FC ≥2 or ≤-2) when comparing time points (dashed outlines): 1wk Dox vs. No Dox, 1wk WD vs. 1wk Dox, and 1wk WD vs. No Dox.



Figure S6. Temporal changes in gene expression profiles of islet cell subpopulations by RNA-sequencing. (A) Normalized expression of selected genes in isolated β cell (blue), EC (green), and MΦ (red) samples. ECM, extracellular matrix. Numbers listed on heat map in 1wk Dox and 1wk WD columns represent fold-change ≥2 or <-2 ($p<0.05$) as compared to No Dox. **(B)** Ingenuity Pathway Analysis (IPA) was applied to fold-change data (1wk Dox vs. No Dox, 1wk WD vs. 1wk Dox, and 1wk WD vs. No Dox) for β cell, EC, and MΦ populations. Pathways showing significant regulation (z-score ≥2 or ≤-2, $p<0.05$) in at least two cell types are shown; a full list is provided in **Table S1**. Z-scores of relevant comparisons are listed on heat map.

Figure S7. Biological processes enriched in islet macrophages, endothelial cells, and β cells of βVEGF-A mice during β cell loss and recovery. Venn diagrams showing profiles of β cells **(A)**, endothelial cells (ECs) **(B)**, and macrophages (MΦs) **(C)** as determined by Gene Ontology (GO) term analysis. Processes are organized by pairwise comparisons between time points (1wk Dox vs. No Dox, 1wk WD vs. 1wk Dox, and 1wk WD vs. No Dox), with location of text in Venn diagram accounting for processes that are represented in multiple time point comparisons. **(D)** Unique and shared processes of β cells, ECs, and MΦs during β cell recovery (1wk WD vs. 1wk Dox and/or 1wk WD vs. No Dox). All terms diagrammed in (**A–D**) appeared in top 20 hits (highest statistical significance) for the indicated population(s); those omitted due to space constraints are provided in **Table S2**.

Table S1: GO Terms for sorted cell populations

			β cells			ECs			Macrophages		
Term	**Process**	**p value:**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**
GO:0000087	M phase of mitotic cell cycle				5.31E-09	1.13E-06		2.30E-10			
GO:0000278	Mitotic cell cycle					3.29E-06		3.37E-10			
GO:0000279	M phase				8.80E-11	3.58E-07		2.60E-14			
GO:0000280	Nuclear division					3.28E-06		1.05E-09			
GO:0000902	Cell morphogenesis					6.64E-05				2.70E-09	6.23E-05
GO:0000904	Cell morphogenesis involved in differentiation					1.59E-06				2.25E-08	3.62E-04
GO:0001501	Skeletal system development		2.97E-08								
GO:0001503	Ossification						3.53E-04		0.002241		
GO:0001525	Angiogenesis		7.92E-13						6.32E-05		
GO:0001568	Blood vessel development		3.64E-21	9.44E-13					6.42E-06		
GO:0001775	Cell activation			1.79E-15	1.55E-12						
GO:0001817	Regulation of cytokine production				1.57E-10						
GO:0001944	Vasculature development		3.10E-22	1.52E-13							5.74E-06
GO:0002504	Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II				5.63E-10						
GO:0002526	Acute inflammatory response						6.27E-05				
GO:0002684	Positive regulation of immune system process			1.63E-13	2.60E-13						
GO:0002694	Regulation of leukocyte activation				4.06E-09						
GO:0006323	DNA packaging							2.18E-04			
GO:0006412	Translation							1.06E-04			6.97E-06
GO:0006811	Ion transport						2.18E-04		5.92E-04		1.36E-05
GO:0006812	Cation transport						1.07E-04		4.04E-04	5.69E-07	9.98E-07
GO:0006813	Potassium ion transport						2.24E-04				3.99E-04
GO:0006836	Neurotransmitter transport										5.17E-04
GO:0006928	Cell motion			1.71E-10							4.89E-04
GO:0006935	Chemotaxis			1.78E-11					0.001387		
GO:0006952	Defense response			1.51E-14	3.64E-11				1.18E-04		
GO:0006954	Inflammatory response			2.18E-15	1.20E-09		2.59E-04		3.41E-06	4.13E-09	

Table S1: GO Terms for sorted cell populations

			β cells			ECs			Macrophages		
Term	**Process**	**p value:**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**
GO:0006955	Immune response		1.35E-10	4.67E-22	6.57E-12				1.12E-10		
GO:0007017	Microtubule-based process							4.58E-06			
GO:0007018	Microtubule-based movement					1.42E-05		8.85E-06			
GO:0007049	Cell cycle				4.50E-09	8.81E-07		4.02E-13			
GO:0007059	Chromosome segregation							1.61E-05			
GO:0007067	Mitosis					3.28E-06		1.05E-09			
GO:0007126	Meiosis							2.02E-04			
GO:0007155	Cell adhesion		1.06E-28	4.21E-36		2.29E-06	6.68E-10		4.43E-10	5.82E-14	9.81E-11
GO:0007156	Homophilic cell adhesion										2.75E-08
GO:0007167	Enzyme linked receptor protein signaling						7.97E-05				
GO:0007169	Transmembrane receptor protein tyrosine kinase signaling pathway						5.49E-05				
GO:0007229	Integrin-mediated signaling pathway			2.45E-11							
GO:0007267	Cell-cell signaling										1.22E-04
GO:0007409	Axonogenesis									2.88E-07	
GO:0007411	Axon guidance					1.55E-04					
GO:0008284	Positive regulation of cell proliferation		9.84E-11						1.03E-06		
GO:0009611	Response to wounding		6.84E-09	8.15E-18			5.42E-04		2.09E-07	3.20E-09	
GO:0015672	Monovalent inorganic cation transport						4.95E-04		8.12E-04		3.65E-06
GO:0016337	Cell-cell adhesion									1.17E-06	4.44E-06
GO:0016477	Cell migration		1.65E-08								7.82E-04
GO:0016485	Protein processing						5.36E-05				
GO:0019886	Antigen processing and presentation of exogenous peptide antigen via MHC class II				1.18E-08						
GO:0022402	Cell cycle process					1.05E-06		2.12E-13			
GO:0022403	Cell cycle phase				2.53E-09	1.90E-07		5.16E-15			
GO:0022610	Biological adhesion		1.32E-28	5.59E-36		2.52E-06	7.21E-10		4.92E-10	6.46E-14	1.07E-10
GO:0030001	Metal ion transport						2.34E-05			1.93E-08	2.25E-06

Table S1: GO Terms for sorted cell populations

			β cells			ECs			Macrophages		
Term	**Process**	**p value:**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**
GO:0030030	Cell projection organization									9.33E-07	
GO:0030155	Regulation of cell adhesion		5.67E-10								
GO:0030182	Neuron differentiation									3.32E-08	9.99E-04
GO:0030198	Extracellular matrix organization		1.11E-13	1.62E-11			6.79E-04				
GO:0030218	Erythrocyte differentiation							9.14E-04			
GO:0031175	Neuron projection development									1.48E-07	
GO:0032940	Secretion by cell						2.48E-04				8.57E-04
GO:0032989	Cellular component morphogenesis					1.22E-04				3.34E-08	6.10E-04
GO:0032990	Cell part morphogenesis									2.09E-07	
GO:0034101	Erythrocyte homeostasis							5.06E-04			
GO:0035295	Tube development		7.39E-09								
GO:0042127	Regulation of cell proliferation		1.27E-14	7.62E-13						8.49E-07	
GO:0042330	Taxis				1.78E-11				0.001387		
GO:0043062	Extracellular structure organization		2.74E-10	5.05E-11		1.18E-04			0.001091	1.38E-06	
GO:0044057	Regulation of system process						7.29E-04				
GO:0045321	Leukocyte activation			4.48E-15	3.83E-12						
GO:0045597	Positive regulation of cell differentiation		2.62E-08								
GO:0045765	Regulation of angiogenesis		3.60E-08								
GO:0045785	Positive regulation of cell adhesion		1.37E-08								
GO:0046649	Lymphocyte activation			3.34E-12	3.00E-10						
GO:0046903	Secretion						7.69E-05				
GO:0048285	Organelle fission					9.66E-06		3.91E-09			
GO:0048514	Blood vessel morphogenesis		7.41E-20	2.09E-12					4.47E-05		
GO:0048666	Neuron development									8.58E-09	
GO:0048667	Cell morphogenesis involved in neuron differentiation					5.62E-05				1.10E-08	
GO:0048812	Neuron projection morphogenesis					2.34E-04				1.70E-07	
GO:0048858	Cell projection morphogenesis									5.79E-08	7.17E-04

Table S1: GO Terms for sorted cell populations

			β cells			ECs			Macrophages		
Term	**Process**	**p value:**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**	**G1vG0**	**G2vG0**	**G2vG1**
GO:0050863	Regulation of T cell activation				6.50E-09						
GO:0050865	Regulation of cell activation				1.74E-09						
GO:0050867	Positive regulation of cell activation				4.69E-09						
GO:0050870	Positive regulation of T cell activation				4.71E-11						
GO:0051094	Positive regulation of developmental process		3.48E-09								
GO:0051249	Regulation of lymphocyte activation				6.63E-09						
GO:0051301	Cell division					5.30E-06		8.55E-10			
GO:0051321	Meiotic cell cycle							2.82E-04			
GO:0051327	M phase of meiotic cell cycle							2.02E-04			
GO:0051604	Protein maturation						1.15E-04				
GO:0051605	Protein maturation by peptide bond cleavage						4.52E-06				
GO:0060348	Bone development								0.001779		

Table S2: Mouse strains utilized in experimental models

Abbreviation	MGI Nomenclature or Strain Name	References
Cd5-CreER	Tg(Cdh5-cre/ERT2)#Ykub	Okabe *et al.*, 2014[22]
MIP-GFP	B6.Cg-Tg(Ins1-EGFP)1Hara/J	Hara et al., 2003[90]
RIP-rtTA	Tg(Ins2-rtTA)2Efr	Milo-Landesman *et al.*, 2001[88]
TetO-VEGF	n/a	Efrat *et al.*, 1995[87]; Ohno-Matsui *et al.*, 2002[89]
VEGFR2$^{fl/fl}$	Kdr^{tm2Sato}	Hooper *et al.*, 2009[98]

Table S3: Breeding scheme to generate βVEGF-A; VEGFR2$^{i\Delta EC}$ mice

Cross	Male breeder	Female breeder	Desired Offspring	Frequency
A1	Cd5-CreER$^{tg/+}$	VEGFR2$^{fl/fl}$	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/+}$	*50%*
A2	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/+}$	VEGFR2$^{fl/fl}$	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/fl}$	*25%*
A3	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/fl}$	RIP-rtTA$^{tg/tg}$	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/+}$; RIP-rtTA$^{tg/+}$	*50%*
A4	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/+}$; RIP-rtTA$^{tg/+}$	VEGFR2$^{fl/fl}$	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/fl}$; RIP-rtTA$^{tg/+}$	*12.5%*
B1	VEGFR2$^{fl/fl}$	TetO-VEGFA$^{tg/tg}$	TetO-VEGFA$^{tg/+}$; VEGFR2$^{fl/+}$	*100%*
B2	TetO-VEGFA$^{tg/+}$; VEGFR2$^{fl/+}$	TetO-VEGFA$^{tg/tg}$	TetO-VEGFA$^{tg/tg}$; VEGFR2$^{fl/+}$	*50%*
B3	TetO-VEGFA$^{tg/+}$; VEGFR2$^{fl/+}$	TetO-VEGFA$^{tg/tg}$; VEGFR2$^{fl/+}$	TetO-VEGFA$^{tg/tg}$; VEGFR2$^{fl/fl}$	*25%*
C1	Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/fl}$; RIP-rtTA$^{tg/+}$	TetO-VEGFA$^{tg/tg}$; VEGFR2$^{fl/fl}$	TetO-VEGFA$^{tg/+}$; Cd5-CreER$^{tg/+}$; VEGFR2$^{fl/fl}$; RIP-rtTA$^{tg/+}$	*25%*

Table S4: PCR primers and conditions for genotyping

Gentoype	Primers	PCR Conditions	Product(s)
Cd5-CreER	5′- GCG GTC TGG CAG TAA AAA CTA TC -3′ 3′- TT CAC TGT CGT TAC GAC AAA GTG -5′	93°C 3’ ---------- 93°C 20” 60°C 20” 30 cycles 72°C 45” ---------- 72°C 5’ 4°C hold	100 bp
MIP-GFP	5′- AAG TTC ATC TGC ACC ACC G -3′ (GFP) 3′- GC GTG GTA GAA GAA GTT CCT -5′ (GFP) 5′- CTA GGC CAC AGA ATT GAA AGA TCT -3′ (IC) 3′- C CTA CTA CGA TCT TAA AGG TGG ATG -5′ (IC)	94°C 1.5’ ---------- 94°C 30” 60°C 1’ 35 cycles 72°C 1’ ---------- 72°C 2’ 4°C hold	173 bp (*GFP*) 324 bp (IC)
RIP-rtTA	5′- GTG AAG TGG GTC CGC GTA CAG -3′ 3′- CTA CGG GAA CCT TAA CTG CTC ATG -5′	92°C 2’ ---------- 94°C 30” 57°C 30” 30 cycles 72°C 30” ---------- 72°C 10’ 4°C hold	400 bp
TetO-VEGF	5′- TCG AGT AGG CGT GTA CGG -3′ 3′- GCT ACG CCC CCG ACG ACG -5′	95°C 4’ ---------- 95°C 1’ 57°C 30” 29 cycles 72°C 1’ ---------- 72°C 10’ 4°C hold	420 bp
VEGFR2$^{fl/fl}$	5′ - CCA CAG AAC AAC TCA GGG CTA - 3′ 3′- AA AGG TCT CTG AAA CGA GGG -5′	94°C 2’ ---------- 94°C 20” 65°C 15” 10 cycles 68°C 10” ---------- 94°C 15” 60°C 15” 28 cycles 72°C 10” ---------- 72°C 1’ 4°C hold	179 bp (*VEGFR2*) 230 bp (*VEGFR2*^{loxP})

GFP, green fluorescent protein; IC, internal control

Table S5: Antibodies used for immunohistochemistry and flow cytometry

Antigen/Conjugate	Species	Source	Catalog #	Application	Dilution
Caveolin-1	Rabbit	Abcam	ab2910	IHC (1º)	1:2000
CD11b – APC	Rat	BD Pharmingen	561690	FC	1:100
CD206 (Mrc1)	Rat	BioLegend	141701	IHC (1º)	1:500
CD31	Rat	BD Pharmingen	553370	IHC (1º)	1:100
CD31 – PE	Rat	BD Pharmingen	561073	FC	1:500
Col-IV	Rabbit	Abcam	ab6586	IHC (1º)	1:1000
Goat IgG – Cy3	Donkey	Jackson Immunoresearch	705-165-147	IHC (2º)	1:500
Guinea pig IgG – Cy2	Donkey	Jackson Immunoresearch	706-225-148	IHC (2º)	1:500
Guinea pig IgG – Cy5	Donkey	Jackson Immunoresearch	706-175-148	IHC (2º)	1:200
Iba1	Rabbit	Wako	019-19741	IHC (1º)	1:500
Iba1	Rabbit	Abcam	ab221790	IHC (1º)	1:1000
Insulin	Guinea pig	Dako	A0564	IHC (1º)	1:1000
Insulin	Guinea pig	Cell Marque	273A-15	IHC (1º)	1:500
Ki67	Rabbit	Abcam	ab15580	IHC (1º)	1:5000
pERK	Rabbit	Cell Signaling	4370	IHC (1º)	1:200
Rabbit IgG – Cy2	Donkey	Jackson Immunoresearch	711-225-152	IHC (2º)	1:500
Rabbit IgG – Cy3	Donkey	Jackson Immunoresearch	711-165-152	IHC (2º)	1:500
Rat IgG – Cy2	Donkey	Jackson Immunoresearch	712-225-153	IHC (2º)	1:500
VEGF-A	Goat	R&D Systems	AF564	IHC (1º)	1:200
VEGFR2	Goat	R&D Systems	AF644	IHC (1º)	1:2000

1º, primary antibody; 2º, secondary antibody; FC, flow cytometry; IHC, immunohistochemistry